Anti-CD40l / Anti-CD28 bispecific antibody and use thereof

The anti-CD40L/anti-CD28 bispecific antibody provides a targeted treatment for autoimmune diseases and graft-versus-host disease by inhibiting CD40L and CD28 co-stimulatory molecules, addressing the limitations of conventional therapies with improved safety and efficacy.

WO2024237744A1PCT designated stage expired Publication Date: 2024-11-21SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/006813
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-18
Filing Date
2024-05-20
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Conventional treatments for autoimmune diseases and graft-versus-host disease using immunosuppressants are limited by their inability to selectively suppress autoimmune responses while maintaining immunity to external pathogens, leading to side effects such as thromboembolic symptoms and T cell activation issues with existing anti-CD40L and anti-CD28 antibodies.

Method used

Development of an anti-CD40L/anti-CD28 bispecific antibody that combines an anti-CD40L antibody and an anti-CD28 antibody, specifically designed to target and inhibit CD40L and CD28 co-stimulatory molecules without causing thromboembolic side effects or T cell activation, using antigen-binding fragments like scFv without an Fc region to prevent dimerization.

Benefits of technology

The bispecific antibody effectively suppresses autoimmune responses, inhibits cytokine secretion, and prevents T cell activation, offering a safer and more targeted treatment for autoimmune diseases and graft-versus-host disease without the adverse effects of conventional therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024006813_21112024_PF_FP_ABST
    Figure KR2024006813_21112024_PF_FP_ABST
Patent Text Reader

Abstract

An anti-CD40L / anti-CD28 bispecific antibody of the present application comprises anti-CD40L scFv and anti-CD28 scFv, and thus exhibits no thromboembolic side effects, can exhibit an excellent effect of treating autoimmune diseases and / or graft-versus-host diseases while preventing a T cell activation effect caused by CD28 dimer formation, and can exhibit excellent bispecific antibody physical properties.
Need to check novelty before this filing date? Find Prior Art

Description

Anti-CD40L / anti-CD28 bispecific antibodies and uses thereof

[0001] Cross-citation with related application(s)

[0002] This application claims the benefit of priority from Republic of Korea Patent Application No. 10-2023-0064576, dated May 18, 2023, the entire contents of which are incorporated herein by reference.

[0003] The present application relates to anti-CD40L antibodies, anti-CD28 antibodies, anti-CD40L / anti-CD28 bispecific antibodies and uses thereof.

[0004]

[0005] Approximately 80 autoimmune diseases exist worldwide, and over 300 million people are estimated to suffer from these diseases. Traditionally, autoimmune diseases have been treated with immunosuppressants or anti-inflammatory drugs, which suppress the body's immune cells. However, these are symptomatic treatments that only suppress final tissue damage, making it difficult to halt the progression of the disease because they do not eliminate the underlying cause. Furthermore, the use of general immunosuppressants can reduce immunity to external pathogens, which can lead to the side effect of infectious diseases, making their continued use difficult.

[0006] Therefore, rather than suppressing overall immunity, active development of treatments (immune tolerance inducers) that maintain immune responses to external pathogens and suppress autoimmune responses by selectively suppressing and eliminating only immune responses to specific autoantigens is underway.

[0007] Accordingly, antibody therapeutics targeting CD40L and CD28, which are known as representative T-lymphocyte costimulatory molecules, are being developed. However, conventional anti-CD40L antibodies have been reported to have the side effect of causing thromboembolic symptoms by promoting platelet activation through cross-linking of the Fc region of the antibody with FcγRIIa located on platelets. In addition, conventional anti-CD28 antibodies had the problem of activating T cells through dimerization alone.

[0008] Accordingly, the inventors of the present application propose a novel anti-CD40L antibody, an anti-CD28 antibody, a bispecific antibody comprising the above antibodies, and their use as a therapeutic agent for autoimmune diseases and / or graft-versus-host diseases, which solve the above-mentioned problems.

[0009]

[0010] One aspect provides an anti-CD40L / anti-CD28 bispecific antibody comprising:

[0011] (1) an anti-CD40L antibody or antigen-binding fragment thereof as a CD40L targeting moiety capable of specifically recognizing and / or binding to the CD40L protein; and

[0012] (2) An anti-CD28 antibody or antigen-binding fragment thereof as a CD28 targeting moiety capable of specifically recognizing and / or binding to the CD28 protein.

[0013] Another aspect provides an anti-CD40L antibody or antigen-binding fragment thereof.

[0014] Another aspect provides an anti-CD28 antibody or antigen-binding fragment thereof.

[0015] Another aspect provides a pharmaceutical composition for the prevention, improvement or treatment of at least one selected from the group consisting of autoimmune diseases and graft-versus-host diseases, comprising the anti-CD40L / anti-CD28 bispecific antibody, the anti-CD40L antibody or antigen-binding fragment thereof, and / or the anti-CD28 antibody or antigen-binding fragment thereof.

[0016] Another aspect provides a use of the anti-CD40L / anti-CD28 bispecific antibody, the anti-CD40L antibody or antigen-binding fragment thereof, and / or the anti-CD28 antibody or antigen-binding fragment thereof for the prevention, improvement or treatment of one or more selected from the group consisting of autoimmune diseases and graft-versus-host diseases.

[0017] Another aspect provides the use of the anti-CD40L / anti-CD28 bispecific antibody, the anti-CD40L antibody or antigen-binding fragment thereof, and / or the anti-CD28 antibody or antigen-binding fragment thereof in the manufacture of a pharmaceutical composition for the prevention, improvement or treatment of one or more diseases selected from the group consisting of autoimmune diseases and graft-versus-host diseases.

[0018] Another aspect provides a method for preventing, improving or treating at least one autoimmune disease and graft-versus-host disease, comprising administering to a subject in need of prevention, improvement or treatment at least one autoimmune disease and graft-versus-host disease, the method comprising administering the anti-CD40L / anti-CD28 bispecific antibody, the anti-CD40L antibody or antigen-binding fragment thereof, and / or the anti-CD28 antibody or antigen-binding fragment thereof. The method may further comprise, prior to the administering step, a step of identifying a subject in need of prevention, improvement or treatment at least one autoimmune disease and graft-versus-host disease.

[0019] Another aspect provides a polynucleotide encoding the anti-CD40L / anti-CD28 bispecific antibody, the anti-CD40L antibody or antigen-binding fragment thereof, and / or the anti-CD28 antibody or antigen-binding fragment thereof.

[0020] Another aspect provides a recombinant vector comprising the polynucleotide. The recombinant vector can be used as an expression vector for a polynucleotide encoding the anti-CD40L / anti-CD28 bispecific antibody, the anti-CD40L antibody or an antigen-binding fragment thereof, and / or the anti-CD28 antibody or an antigen-binding fragment thereof.

[0021] Another aspect provides a cell comprising the anti-CD40L / anti-CD28 bispecific antibody, the anti-CD40L antibody or antigen-binding fragment thereof, and / or a polynucleotide encoding the anti-CD28 antibody or antigen-binding fragment thereof. The cell may be a recombinant cell transformed with a recombinant vector comprising the polynucleotide.

[0022] Another aspect provides a method for producing the anti-CD40L / anti-CD28 bispecific antibody, the anti-CD40L antibody or antigen-binding fragment thereof, and / or the anti-CD28 antibody or antigen-binding fragment thereof, comprising a step of expressing the polynucleotide in a cell. The step of expressing the polynucleotide can be performed by culturing a cell comprising the polynucleotide (e.g., in a recombinant vector) under an environment that allows expression of the polynucleotide.

[0023]

[0024] Definition of terms

[0025] In this specification, “consisting of a sequence,” “consisting essentially of a sequence,” or “comprising a sequence” may mean all instances of including the sequence, but is not intended to exclude instances of including sequences other than the sequence.

[0026] As used herein, the terms “protein or polypeptide comprising or consisting of an amino acid sequence recognized by a sequence number” and “gene or polynucleotide comprising or consisting of a nucleic acid sequence recognized by a sequence number” may refer to a protein (or polypeptide) or gene (or polynucleotide) that consists essentially of the amino acid sequence or nucleic acid sequence, or has at least 90%, at least 91%, at least 92%, at least 93%, at least 94% or more, at least 95% or more, at least 96% or more, at least 97% or more, at least 98% or more, or at least 99% or more sequence identity with the amino acid sequence or nucleic acid sequence while maintaining the inherent activity and / or function.

[0027] The term "antibody" as used herein encompasses a wide variety of biochemically distinguishable polypeptide classes. Those skilled in the art will appreciate that heavy chains are classified as gamma, mu, alpha, delta, or epsilon (γ, μ, α, δ, ε), with some subclasses (e.g., γ1-γ4), and light chains are also classified as kappa or lambda (Κ, λ). It is the properties of these chains that determine the "class" of an antibody, whether it is IgG, IgM, IgA, IgG, or IgE, respectively. Immunoglobulin subclasses (isotypes), such as IgG1, IgG2, IgG3, and IgG4, are well characterized and are known to confer functional specialization.

[0028] An intact antibody comprises two full-length light chains and two full-length heavy chains, each light chain being linked to a heavy chain by a disulfide bond. Antibodies have heavy-chain constant regions and light-chain constant regions. The heavy-chain constant regions are of the gamma (γ), mu (μ), alpha (α), delta (δ), or epsilon (ε) type, which can be further classified as gamma 1 (γ1), gamma 2 (γ2), gamma 3 (γ3), gamma 4 (γ4), alpha 1 (α1), or alpha 2 (α2). The light-chain constant regions can be of the kappa (κ) or lambda (λ) type.

[0029] The term "heavy chain" refers to a variable region V containing sufficient amino acid sequence to provide specificity for an antigen. H , and three invariant regions C H1 , C H2 and C H3 , and a hinge region. The term "light chain" refers to a variable region V comprising an amino acid sequence sufficient to provide specificity for an antigen. L- and invariant region C L It may refer to a full-length light chain or a fragment thereof.

[0030] The term "complementarity determining region (CDR)" refers to an amino acid sequence found in the hypervariable region of the heavy or light chain of an immunoglobulin. Heavy and light chains may each contain three CDRs (CDRH1, CDRH2, and CDRH3; and CDRL1, CDRL2, and CDRL3). CDRs may provide residues that play a key role in binding an antibody to an antigen or epitope. The terms "specifically bind" or "specifically recognize" are well known to those skilled in the art and indicate that an antibody and an antigen specifically interact to induce immunological activity.

[0031] The antibody may be an animal-derived antibody (e.g., a mouse-derived antibody or a chicken-derived antibody), a chimeric antibody (e.g., a mouse-human chimeric antibody or a chicken-human chimeric antibody), or a humanized antibody. The antibody or antigen-binding fragment may be isolated from a living organism or non-naturally occurring. The antibody or antigen-binding fragment may be recombinantly or synthetically produced (not naturally occurring).

[0032] In another example, the antibody may be derived (isolated) from any animal, including mammals, birds, and the like, including humans. For example, the antibody may be an antibody from a human, mouse, donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken. Here, a human antibody is an antibody having an amino acid sequence of a human immunoglobulin, and includes an antibody isolated from a human immunoglobulin library or an antibody isolated from an animal that has been transgenic for one or more human immunoglobulins and does not express endogenous immunoglobulins.

[0033] The antibody may be a monoclonal antibody or a polyclonal antibody, for example, a monoclonal antibody. The monoclonal antibody may be produced using methods widely known in the art. For example, it may be produced using phage display techniques.

[0034] Animal-derived antibodies, produced by immunizing animals with a desired antigen, can generally elicit immune rejection when administered to humans for therapeutic purposes. Chimeric antibodies have been developed to suppress this immune rejection. Chimeric antibodies are created by genetically engineering the constant region of an animal-derived antibody, which is responsible for the anti-isotypic response, to replace it with the constant region of a human antibody. While chimeric antibodies significantly improve anti-isotypic responses compared to animal-derived antibodies, the presence of animal-derived amino acids in the variable region still carries the potential for adverse reactions due to anti-idiotypic responses. Humanized antibodies were developed to mitigate these side effects. These antibodies are produced by grafting the CDRs (complementarity determining regions), which play a crucial role in antigen binding, from the variable region of a chimeric antibody onto a human antibody framework.

[0035] As used herein, the term "antigen-binding fragment" refers to a fragment derived from a complete immunoglobulin structure that includes a portion capable of binding to an antigen, such as a CDR. For example, the antigen-binding fragment may be, but is not limited to, scFv, (scFv)2, Fab, Fab', or F(ab')2. In the present invention, the antigen-binding fragment may be, for example, an antibody-derived fragment that includes at least one complementarity determining region selected from the group consisting of scFv, (scFv)2, scFv-Fc, Fab, Fab', and F(ab')2.

[0036] In one example, the antigen binding fragment may be, but is not limited to, an antigen binding fragment without an Fc region, such as scFv, Fv, (scFv)2, Fab, Fab', F(ab')2, or a single domain antibody without an Fc region.

[0037] In one example, the antigen binding fragment may be in the form of a monovalent antibody, such as, but not limited to, a single domain antibody in the form of scFv, Fv, Fab, Fab' or a monovalent antibody.

[0038] Among antigen-binding fragments, Fab has a structure with variable regions of the light and heavy chains, constant region of the light chain, and first constant region (CH1) of the heavy chain, and has one antigen-binding site.

[0039] Fab' differs from Fab in that it has a hinge region containing one or more cysteine ​​residues at the C-terminus of the heavy chain CH1 domain. F(ab')2 antibodies are formed through disulfide bonds between cysteine ​​residues in the hinge region of Fab'.

[0040] Fv is the minimum antibody fragment that has only a heavy chain variable region and a light chain variable region, and the recombinant technology for producing Fv fragments is well known in the art. A two-chain Fv has a heavy chain variable region and a light chain variable region linked non-covalently, and a single-chain Fv has a heavy chain variable region and a single chain variable region covalently linked, usually via a peptide linker, or directly linked at the C-terminus, so that they can form a dimer-like structure like a two-chain Fv.

[0041] The above antigen-binding fragment can be obtained using a proteolytic enzyme (for example, Fab can be obtained by restriction digestion of the whole antibody with papain, and F(ab')2 fragment can be obtained by digestion with pepsin), and can be produced through genetic recombination technology.

[0042] The term "hinge region" refers to a region contained in the heavy chain of an antibody, which exists between the CH1 and CH2 regions and functions to provide flexibility to the antigen-binding site within the antibody.

[0043] The immunoglobulin (e.g., human immunoglobulin) or antibody molecule of the present disclosure can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, IgY, etc.), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, etc.) or subclass of immunoglobulin molecule.

[0044] In antibodies or antibody fragments, portions other than the CDRs or variable regions (e.g., constant regions) may be derived from a human antibody, and in particular, they may be derived from, for example, IgG, IgA, IgD, IgE, IgM or IgY, such as IgG1, IgG2, IgG 3 or IgG4.

[0045] As used herein, the term "peptide linker" may refer to an oligopeptide comprising 1 to 100 amino acids, particularly 2 to 50 amino acids, each of which may be any amino acid without limitation. Any conventional peptide linker may be used with or without appropriate modifications to suit a specific purpose. In certain embodiments, the peptide linker may comprise, for example, Gly, Asn, and / or Ser residues, and / or neutral amino acids such as Thr and / or Ala. Suitable amino acid sequences for peptide linkers may be known. In the related art, the length of the peptide linker may be appropriately determined as long as the function of the antibody and / or scFv is not affected. For example, the peptide linker may be formed of 1 to 100 amino acids, 2 to about 50 amino acids, or 5 to 25 amino acids, each of which may be selected from the group consisting of Gly, Asn, Ser, Thr, and Ala. In one embodiment, the peptide linker is (G m S l ) n (m, l, and n are "G", "S", and "(G m S l )), each independently selected from an integer of about 1 to about 10, in particular, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In one example, the peptide linker may comprise the amino acid sequence of GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93) or GQSSRSSSGGGSSGGGGS (SEQ ID NO: 118).

[0046]

[0047] CD40L targeting moiety

[0048] CD40L is a member of the TNF family of molecules primarily expressed on activated T cells (including Th0, Th1, and Th2 subtypes) and is known to form homotrimers similar to other members of this family. Furthermore, CD40L has been found to be expressed on mast cells, as well as activated basophils and eosinophils. CD40L binds to the CD40 receptor (CD40R) on antigen-presenting cells (APCs), which can induce various effects depending on the target cell type. Generally, CD40L acts as a costimulatory molecule and can induce activation in APCs in conjunction with T cell receptor stimulation by MHC molecules on APCs.

[0049] The term "CD40L" may refer to both full-length CD40L and soluble fragments of CD40L resulting from proteolysis, such as the extracellular domain form. The amino acid sequences of membrane-bound and soluble forms of human CD40L (e.g., Swissprot: P29965) are available from publicly available databases.

[0050] CD40L (also known as CD154, CD40 ligand, gp39, or TBAM) is a type II membrane glycoprotein of approximately 33 kDa (Swiss-ProtAcc-No. P29965). Additionally, a shorter, soluble form of CD40L, 18 kDa (also known as sCD40L or soluble CD40L), exists. These soluble forms of CD40L are generated by proteolytic processing of the membrane-bound protein, but the cellular activity of the soluble form is known to be poor in the absence of higher-order oligomerization (e.g., trimerization).

[0051] CD40L (Cluster of Differentiation 40 ligand) is a type II transmembrane protein with a variable molecular weight ranging from 32 to 39 kDa due to post-translational modification. CD40L belongs to the tumor necrosis factor superfamily and exists as a CD40L trimer due to its sandwich extracellular structure. CD40L is primarily expressed on activated T cells, but is also known to be expressed on activated B cells and platelets.

[0052] The above CD40L may be, but is not limited to, human CD40L, mouse CD40L, monkey CD40L, donkey CD40L, sheep CD40L, rabbit CD40L, goat CD40L, guinea pig CD40L, camel CD40L, horse CD40L, or chicken CD40L.

[0053] In one example, the anti-CD40L antibody or antigen-binding fragment thereof may exhibit a beneficial effect of preventing thrombotic side effects by not comprising an Fc portion.

[0054] In one example, the antigen-binding fragment of the anti-CD40L antibody may not comprise an Fc portion and / or may be in the form of a monovalent antibody.

[0055] In one example, the antigen-binding fragment of the anti-CD40L antibody may be, but is not limited to, an antigen-binding fragment lacking an Fc region, such as scFv, Fv, (scFv)2, Fab, Fab', F(ab')2, or a single domain antibody lacking an Fc region.

[0056] In one example, the anti-CD40L antibody or antigen-binding fragment thereof may be an anti-CD40L scFv.

[0057] In one aspect, the anti-CD40L antibody or antigen-binding fragment thereof may comprise:

[0058] L-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, 2 or 3;

[0059] L-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, 5 or 6;

[0060] L-CDR3 comprising the amino acid sequence of SEQ ID NO: 7, 8 or 9;

[0061] H-CDR1 comprising the amino acid sequence of SEQ ID NO: 10, 11 or 12;

[0062] H-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, 14 or 15; and

[0063] H-CDR3 comprising the amino acid sequence of SEQ ID NO: 16, 17 or 18.

[0064] The amino acid sequences of the complementarity determining regions (CDRs) of the above anti-CD40L antibodies or antigen-binding fragments thereof are illustrated in Table 1 below:

[0065] Named sequence Sequence numberL-CDR1SGGYSSYGIYYYG1L-CDR1SGDSSWYG2L-CDR1SGGSGSYG3L-CDR2NGNKRPS4L-CDR2ANTNRPS5 L-CDR2WDDERPS6L-CDR3GSGDSSSDSGI7L-CDR3GSADSTYTAA8L-CDR3GGYDDSSYAGI9H-CDR1GFTFSSYGMN10H -CDR1GFDFSSYDMN11H-CDR1GFTFSSYGMQ12H-CDR2AISNDGSSTSYAPAVKG13H-CDR2GIYDDGSGTVYAPAVKG14H -CDR2AIDDDGSSTNYGAAVKG15H-CDR3ESTNGGWVADDIDA16H-CDR3GGGADNIDA17H-CDR3DGIIYYWNADAGYIDA18

[0066] For example, the anti-CD40L antibody or antigen-binding fragment thereof may comprise: (1) an L-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, an L-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, an L-CDR3 comprising the amino acid sequence of SEQ ID NO: 7, an H-CDR1 comprising the amino acid sequence of SEQ ID NO: 10, an H-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 16;

[0067] (2) L-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, L-CDR2 comprising the amino acid sequence of SEQ ID NO: 5, L-CDR3 comprising the amino acid sequence of SEQ ID NO: 8, H-CDR1 comprising the amino acid sequence of SEQ ID NO: 11, H-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and H-CDR3 comprising the amino acid sequence of SEQ ID NO: 17; or

[0068] (3) L-CDR1 comprising the amino acid sequence of SEQ ID NO: 3, L-CDR2 comprising the amino acid sequence of SEQ ID NO: 6, L-CDR3 comprising the amino acid sequence of SEQ ID NO: 9, H-CDR1 comprising the amino acid sequence of SEQ ID NO: 12, H-CDR2 comprising the amino acid sequence of SEQ ID NO: 15, and H-CDR3 comprising the amino acid sequence of SEQ ID NO: 18.

[0069]

[0070] In one aspect, the anti-CD40L antibody or antigen-binding fragment thereof may comprise:

[0071] L-CDR1 comprising the amino acid sequence of SEQ ID NO: 1 or 2;

[0072] L-CDR2 comprising the amino acid sequence of SEQ ID NO: 4 or 5;

[0073] L-CDR3 comprising the amino acid sequence of SEQ ID NO: 7 or 8;

[0074] H-CDR1 comprising the amino acid sequence of SEQ ID NO: 10 or 11;

[0075] H-CDR2 comprising the amino acid sequence of SEQ ID NO: 13 or 14; and

[0076] H-CDR3 comprising the amino acid sequence of SEQ ID NO: 16 or 17.

[0077] For example, the anti-CD40L antibody or antigen-binding fragment thereof may comprise:

[0078] (1) L-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, L-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, L-CDR3 comprising the amino acid sequence of SEQ ID NO: 7, H-CDR1 comprising the amino acid sequence of SEQ ID NO: 10, H-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and H-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; or

[0079] (2) L-CDR1 comprising the amino acid sequence of SEQ ID NO: 2, L-CDR2 comprising the amino acid sequence of SEQ ID NO: 5, L-CDR3 comprising the amino acid sequence of SEQ ID NO: 8, H-CDR1 comprising the amino acid sequence of SEQ ID NO: 11, H-CDR2 comprising the amino acid sequence of SEQ ID NO: 14, and H-CDR3 comprising the amino acid sequence of SEQ ID NO: 17.

[0080]

[0081] The anti-CD40L antibody or antigen-binding fragment thereof comprises a light chain variable region comprising an L-CDR1 comprising an amino acid sequence of SEQ ID NO: 1, 2 or 3; an L-CDR2 comprising an amino acid sequence of SEQ ID NO: 4, 5 or 6; and an L-CDR3 comprising an amino acid sequence of SEQ ID NO: 7, 8 or 9; and

[0082] It may comprise a heavy chain variable region comprising an H-CDR1 comprising the amino acid sequence of SEQ ID NO: 10, 11, or 12; an H-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, 14, or 15; and an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 16, 17, or 18.

[0083] In one example, the amino acid sequence of the framework of the variable region of the anti-CD40L antibody or antigen-binding fragment thereof is illustrated in Table 2 below:

[0084] Named Sequence SEQ ID NO:L-FR1ALTQPSSVSANLGGTVKITC19L-FR1ELTQDPAVSVALGQTVRITC20L-FR1LTQASSVSANLGGTVEITC21L-FR1LTQPSSV SANPGETVKITC22L-FR2WYQQKSPGSAPVTLIY23L-FR2WYQQKPGQAPVTVIY24L-FR3NIPSRFSGSTSGSTNTLTITGVQVDDEAVYFC25L- FR3GIPDRFSGSSSGNTASLTITGAQAEDEADYYC26L-FR3DIPSRFSGSTSGSTGTLTITGVQADDEAVYYC27L-FR3DIPSRFSGSKSGSTATLTI TGVQAEDEAVYFC28L-FR4FGAGTTLTVL29L-FR4FGGGTKLTVL30L-FR4FGAGTTLTVL31H-FR1AVTLDESGGGLQTPGGALSLVCKAS32H-F R1EVQLVESGGGLVQPGGSLRLSCAAS33H-FR1EVQLVESGGGLVQPGGSLRLICAAS34H-FR1AVTLDESGGGLQTPGGTLSLVCKAS35H-FR1AV TLDESGGGLHTPGGALSLVCKAS36H-FR2WVRQAPGKGLEWVG37H-FR2WVRQAPGKGLEWVS38H-FR2WVRQAPGKGLEYVA39H-FR2WVRQAPG KGLEFVA40H-FR3RATISRDNGQSTVRLQLNNLRAEDTATYYCAK41H-FR3RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK42H-FR3RATISRDN GQSTVRLQLNNLRAEDTGTYYCTR43H-FR3RATISRDNGQSTVRLQLNNLRAEDTGTYYCAK44H-FR4WGHGTEVIVSS45H-FR4WGQGTLVTVSS46

[0085] For example, the anti-CD40L antibody or antigen-binding fragment thereof may comprise:

[0086] a light chain variable region comprising the amino acid sequence of SEQ ID NO: 47, 48, 49, 50 or 128; and

[0087] A heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 51, 52, 53, 54, 55, 56, or 57.

[0088] For example, the anti-CD40L antibody or antigen-binding fragment thereof may comprise:

[0089] A light chain variable region comprising the amino acid sequence of SEQ ID NO: 47, 48, 49, or 128; and

[0090] A heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 51, 52, 53, 54, 55, or 56.

[0091]

[0092] The amino acid sequence of the variable region of the above anti-CD40L antibody or antigen-binding fragment thereof is illustrated in Table 3 below:

[0093]

[0094] In the light chain variable region and heavy chain variable region of Table 3 above, each complementarity determining region is underlined.

[0095]

[0096] In one example, the anti-CD40L antibody or antigen-binding fragment thereof may comprise:

[0097] (1) a light chain variable region comprising an amino acid sequence of SEQ ID NO: 47; and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 51;

[0098] (2) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 48; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 52, 53, 54, or 55;

[0099] (3) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 49; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56; or

[0100] (4) A light chain variable region comprising the amino acid sequence of SEQ ID NO: 50; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 57.

[0101] In one example, the anti-CD40L antibody or antigen-binding fragment thereof may comprise:

[0102] (1) a light chain variable region comprising an amino acid sequence of SEQ ID NO: 47; and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 51;

[0103] (2) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 48; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 52, 53, 54, or 55; or

[0104] (3) A light chain variable region comprising the amino acid sequence of SEQ ID NO: 49; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56.

[0105]

[0106] In one example, the anti-CD40L antibody or antigen-binding fragment thereof may be a scFv (single chain variable fragment) comprising:

[0107] A light chain variable region comprising an L-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, 2 or 3; an L-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, 5 or 6; and an L-CDR3 comprising the amino acid sequence of SEQ ID NO: 7, 8 or 9; and

[0108] A heavy chain variable region comprising an H-CDR1 comprising the amino acid sequence of SEQ ID NO: 10, 11, or 12; an H-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, 14, or 15; and an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 16, 17, or 18.

[0109] In one example, the anti-CD40L scFv may comprise:

[0110] A light chain variable region comprising an L-CDR1 comprising the amino acid sequence of SEQ ID NO: 1 or 2; an L-CDR2 comprising the amino acid sequence of SEQ ID NO: 4 or 5; and an L-CDR3 comprising the amino acid sequence of SEQ ID NO: 7 or 8; and

[0111] A heavy chain variable region comprising an H-CDR1 comprising the amino acid sequence of SEQ ID NO: 10 or 11; an H-CDR2 comprising the amino acid sequence of SEQ ID NO: 13 or 14; and an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 16 or 17.

[0112] In one example, the anti-CD40L scFv may comprise:

[0113] a light chain variable region comprising the amino acid sequence of SEQ ID NO: 47, 48, 49, 50 or 128; and

[0114] A heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 51, 52, 53, 54, 55, 56, or 57.

[0115] In one example, the anti-CD40L scFv may comprise:

[0116] A light chain variable region comprising the amino acid sequence of SEQ ID NO: 47, 48, 49, or 128; and

[0117] A heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 51, 52, 53, 54, 55, or 56.

[0118] In one example, the anti-CD40L scFv may comprise:

[0119] (1) a light chain variable region comprising an amino acid sequence of SEQ ID NO: 47; and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 51;

[0120] (2) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 48 or 128; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 52, 53, 54, or 55;

[0121] (3) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 49; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56; or

[0122] (4) A light chain variable region comprising the amino acid sequence of SEQ ID NO: 50; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 57.

[0123] In one example, the anti-CD40L scFv may comprise:

[0124] (1) a light chain variable region comprising an amino acid sequence of SEQ ID NO: 47; and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 51;

[0125] (2) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 48 or 128; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 52, 53, 54, or 55; or

[0126] (3) A light chain variable region comprising the amino acid sequence of SEQ ID NO: 49; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 56.

[0127]

[0128] At this time, the light chain variable region and the heavy chain variable region can be linked to each other in any order directly (e.g., without a linker) or via a peptide linker. The peptide linker is as described above.

[0129] For example, the anti-CD40L scFv may comprise a light chain variable region and a heavy chain variable region in the N'-terminal to C'-terminal direction. Alternatively, the anti-CD40L scFv may comprise a heavy chain variable region and a light chain variable region in the N'-terminal to C'-terminal direction.

[0130] In one example, the anti-CD40L scFv may comprise the amino acid sequence of SEQ ID NO: 58, 59, 60, 61, 62, 63 or 64.

[0131] In one example, the anti-CD40L scFv may comprise the amino acid sequence of SEQ ID NO: 58, 59, 60, 61, 62, or 63.

[0132]

[0133] CD28 targeting moiety

[0134] CD28 (Cluster of Differentiation 28) is a 44-kDa glycoprotein specifically expressed on the surface of T cells, and is known to be an essential factor for T cell activity and survival. Cell signaling through CD28 costimulation is one of the key factors regulating T cell activity and is essential for T cell responses to antigens and T cell-mediated B cell responses.

[0135] The above CD28 may be, but is not limited to, human CD28, mouse CD28, monkey CD28, donkey CD28, sheep CD28, rabbit CD28, goat CD28, guinea pig CD28, camel CD28, horse CD28, or chicken CD28.

[0136] In one example, the antigen-binding fragment of the anti-CD28 antibody has a monovalent antibody form and can thus prevent CD28 dimerization and thus prevent T cell activation.

[0137] In one example, the antigen-binding fragment of the anti-CD28 antibody may not comprise an Fc portion and / or may be in the form of a monovalent antibody.

[0138] In one example, the antigen-binding fragment of the anti-CD28 antibody may be, but is not limited to, an antigen-binding fragment in the form of a monovalent antibody, such as a scFv, Fv, Fab, Fab' or a single domain antibody in the form of a monovalent antibody.

[0139] In one example, the antigen-binding fragment of the anti-CD28 antibody may be an anti-CD28 scFv.

[0140] In another aspect, the anti-CD28 antibody or antigen-binding fragment thereof may comprise:

[0141] L-CDR1 comprising the amino acid sequence of SEQ ID NO: 65;

[0142] L-CDR2 comprising the amino acid sequence of SEQ ID NO: 66;

[0143] L-CDR3 comprising the amino acid sequence of SEQ ID NO: 67;

[0144] H-CDR1 comprising the amino acid sequence of SEQ ID NO: 68 or 69;

[0145] H-CDR2 comprising the amino acid sequence of SEQ ID NO: 70; and

[0146] H-CDR3 comprising the amino acid sequence of SEQ ID NO: 71.

[0147]

[0148] The amino acid sequences of the complementarity determining regions (CDRs) of the above anti-CD28 antibodies or antigen-binding fragments thereof are illustrated in Table 4 below:

[0149] Named sequence SEQ ID NO:L-CDR1SGGGSSNNYG65L-CDR2YNDKRPS66L-CDR3GSRDSSHDGI67H-CDR1GFTFSTFNMF68H-CDR1GFTFSSYAMH69H-CDR2QISSNDGSWTGYGAAVKG70H-CDR3AAGGYNVCGYGCGGDYIDA71

[0150] For example, the anti-CD28 antibody or antigen-binding fragment thereof may comprise:

[0151] (1) L-CDR1 comprising the amino acid sequence of SEQ ID NO: 65, L-CDR2 comprising the amino acid sequence of SEQ ID NO: 66, L-CDR3 comprising the amino acid sequence of SEQ ID NO: 67, H-CDR1 comprising the amino acid sequence of SEQ ID NO: 68, H-CDR2 comprising the amino acid sequence of SEQ ID NO: 70, and H-CDR3 comprising the amino acid sequence of SEQ ID NO: 71; or

[0152] (2) L-CDR1 comprising an amino acid sequence of SEQ ID NO: 65, L-CDR2 comprising an amino acid sequence of SEQ ID NO: 66, L-CDR3 comprising an amino acid sequence of SEQ ID NO: 67, H-CDR1 comprising an amino acid sequence of SEQ ID NO: 69, H-CDR2 comprising an amino acid sequence of SEQ ID NO: 70, and H-CDR3 comprising an amino acid sequence of SEQ ID NO: 71.

[0153]

[0154] The anti-CD28 antibody or antigen-binding fragment thereof comprises a light chain variable region comprising an L-CDR1 comprising an amino acid sequence of SEQ ID NO: 65, an L-CDR2 comprising an amino acid sequence of SEQ ID NO: 66, and an L-CDR3 comprising an amino acid sequence of SEQ ID NO: 67; and

[0155] It may include a heavy chain variable region comprising an H-CDR1 comprising an amino acid sequence of SEQ ID NO: 68 or 69, an H-CDR2 comprising an amino acid sequence of SEQ ID NO: 70, and an H-CDR3 comprising an amino acid sequence of SEQ ID NO: 71.

[0156] In one example, the amino acid sequence of the framework of the variable region of the anti-CD28 antibody or antigen-binding fragment thereof is illustrated in Table 5 below:

[0157] Name sequence Sequence number L-FR1MTQPSSVSANPGETVKITC72L-FR1LTQPSSVSANPGETVKITC73L-FR2WYQQKSPGSAPVTVIY74L-FR2WYQQKPGSAPVT VIY75L-FR3GIPSRFSGSTSGSTGTLTITGVRAEDEAVYFC76L-FR4FGAGTTLTVL77L-FR4FGGGTKLTVL78H-FR1AVTLDESGGGLQTPGGAL SLVCKAS79H-FR1PVKLVESGGGLVTPGGSLRLSCSAS80H-FR2WVRQAPGKGLEYVA81H-FR2WVRQAPGKGLEYVG82H-FR3RATISRDNGQST VRLQLNNLRAEDTATYYCAK83H-FR3RFTISRDNSKSTLYLQMNSLRAEDTAVYYCAK84H-FR4WGHGTEVIVSSTS85H-FR4WGHGTQVTVSSTS86

[0158] For example, the anti-CD28 antibody or antigen-binding fragment thereof may comprise:

[0159] A light chain variable region comprising the amino acid sequence of SEQ ID NO: 87, 88, 98 or 100; and

[0160] A heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 89, 90, 99, or 101.

[0161] The amino acid sequence of the variable region of the above anti-CD28 antibody or antigen-binding fragment thereof is illustrated in Table 6 below:

[0162] 명명서열서열번호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

[0163] In the light chain variable region and heavy chain variable region of Table 6 above, each complementarity determining region is underlined.

[0164]

[0165] In one example, the anti-CD28 antibody or antigen-binding fragment thereof may comprise:

[0166] (1) a light chain variable region comprising an amino acid sequence of SEQ ID NO: 87; and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 89;

[0167] (2) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 88; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 90;

[0168] (3) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 98; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 99;

[0169] (4) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 99; or

[0170] (5) A light chain variable region comprising the amino acid sequence of SEQ ID NO: 98; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 101.

[0171]

[0172] In one example, the anti-CD28 antibody or antigen-binding fragment thereof

[0173] The above anti-CD28 antibody or antigen-binding fragment thereof may be a scFv comprising:

[0174] A light chain variable region comprising an L-CDR1 comprising the amino acid sequence of SEQ ID NO: 65, an L-CDR2 comprising the amino acid sequence of SEQ ID NO: 66, and an L-CDR3 comprising the amino acid sequence of SEQ ID NO: 67; and

[0175] A heavy chain variable region comprising an H-CDR1 comprising the amino acid sequence of SEQ ID NO: 68 or 69, an H-CDR2 comprising the amino acid sequence of SEQ ID NO: 70, and an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 71.

[0176] In one example, the anti-CD28 scFv may comprise:

[0177] A light chain variable region comprising the amino acid sequence of SEQ ID NO: 87 or 88; and

[0178] A heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 89 or 90.

[0179] In one example, the anti-CD28 scFv may comprise:

[0180] (1) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 87; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 89; or

[0181] (2) A light chain variable region comprising the amino acid sequence of SEQ ID NO: 88; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 90.

[0182]

[0183] At this time, the light chain variable region and the heavy chain variable region can be linked to each other in any order directly (e.g., without a linker) or via a peptide linker. The peptide linker is as described above.

[0184] For example, the anti-CD28 scFv may comprise a light chain variable region and a heavy chain variable region in the N'-terminal to C'-terminal direction. Alternatively, the anti-CD28 scFv may comprise a heavy chain variable region and a light chain variable region in the N'-terminal to C'-terminal direction.

[0185] In one example, the anti-CD28 scFv may comprise the amino acid sequence of SEQ ID NO: 91 or 92.

[0186]

[0187] anti-CD40L / anti-CD28 bispecific antibody

[0188] Another aspect provides anti-CD40L / anti-CD28 bispecific antibodies comprising:

[0189] (1) an anti-CD40L antibody or antigen-binding fragment thereof as a CD40L targeting moiety capable of specifically recognizing and / or binding to CD40L; and

[0190] (2) An anti-CD28 antibody or antigen-binding fragment thereof as a CD28 targeting moiety capable of specifically recognizing and / or binding to CD28.

[0191] The above anti-CD40L / anti-CD28 bispecific antibodies may include:

[0192] (1) an antigen-binding fragment of an anti-CD40L antibody that does not comprise an Fc portion (or Fc region) as a CD40L targeting moiety capable of specifically recognizing and / or binding to CD40L; and

[0193] (2) An antigen-binding fragment of an anti-CD28 antibody in the form of a monovalent antibody, which is a CD28 targeting moiety capable of specifically recognizing and / or binding to CD28.

[0194] In one example, the antigen-binding fragment of the anti-CD40L antibody may be in the form of an anti-CD40L scFv, Fv, (scFv)2, Fab, Fab', F(ab')2 or single domain antibody without an Fc region.

[0195] In one example, the antigen-binding fragment of the anti-CD28 antibody may be in the form of a single domain antibody in the form of an anti-CD28 scFv, Fv, Fab, Fab' or monovalent antibody.

[0196] In one example, the anti-CD40L / anti-CD28 bispecific antibody may comprise:

[0197] (1) an antigen-binding fragment of an anti-CD40L antibody that does not contain an Fc region; and

[0198] (2) Antigen-binding fragment of anti-CD28 antibody in monovalent antibody form.

[0199] The antigen-binding fragment of the anti-CD40L antibody not comprising the Fc region may be in the form of an anti-CD40L scFv, Fv, (scFv)2, Fab, Fab', F(ab')2 or a single domain antibody without an Fc region.

[0200] The antigen-binding fragment of the anti-CD28 antibody in the form of the above monovalent antibody may be in the form of a single domain antibody in the form of an anti-CD28 scFv, Fv, Fab, Fab' or monovalent antibody.

[0201] The antigen-binding fragment of the anti-CD40L antibody included in the above bispecific antibody does not include an Fc region, thereby achieving an advantageous effect of exhibiting binding affinity for the CD40L antigen equivalent to or higher than that of an anti-CD40L antibody including an existing Fc region, and inhibiting co-stimulatory molecules and inhibiting cytokine secretion, while not exhibiting thromboembolic side effects.

[0202] In addition, since the antigen-binding fragment of the anti-CD28 antibody in the form of a monovalent antibody is an antigen-binding fragment in the form of a monovalent antibody, it can achieve an advantageous effect of preventing the T cell activation effect caused by CD28 dimer formation.

[0203]

[0204] In one example, the anti-CD40L / anti-CD28 bispecific antibody may comprise:

[0205] (1) anti-CD40L antibody or antigen-binding fragment thereof; and

[0206] (2) L-CDR1 comprising the amino acid sequence of sequence number 65;

[0207] L-CDR2 comprising the amino acid sequence of SEQ ID NO: 66;

[0208] L-CDR3 comprising the amino acid sequence of SEQ ID NO: 67;

[0209] H-CDR1 comprising the amino acid sequence of SEQ ID NO: 68 or 69;

[0210] H-CDR2 comprising the amino acid sequence of SEQ ID NO: 70; and

[0211] An anti-CD28 antibody or antigen-binding fragment thereof comprising an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 71.

[0212] The anti-CD40L antibody or antigen-binding fragment thereof and the anti-CD28 antibody or antigen-binding fragment thereof are as described above.

[0213] In one example, the anti-CD40L / anti-CD28 bispecific antibody may comprise:

[0214] (1) an antigen-binding fragment of an anti-CD40L antibody that does not contain an Fc region; and

[0215] (2) Antigen-binding fragment of anti-CD28 antibody in monovalent antibody form.

[0216] The antigen-binding fragment of the above anti-CD40L antibody is,

[0217] L-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, 2 or 3;

[0218] L-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, 5 or 6;

[0219] L-CDR3 comprising the amino acid sequence of SEQ ID NO: 7, 8 or 9;

[0220] H-CDR1 comprising the amino acid sequence of SEQ ID NO: 10, 11 or 12;

[0221] H-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, 14 or 15; and

[0222] It may comprise an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 16, 17 or 18.

[0223] The antigen-binding fragment of the above anti-CD28 antibody is,

[0224] L-CDR1 comprising the amino acid sequence of SEQ ID NO: 65;

[0225] L-CDR2 comprising the amino acid sequence of SEQ ID NO: 66;

[0226] L-CDR3 comprising the amino acid sequence of SEQ ID NO: 67;

[0227] H-CDR1 comprising the amino acid sequence of SEQ ID NO: 68 or 69;

[0228] H-CDR2 comprising the amino acid sequence of SEQ ID NO: 70; and

[0229] It may include an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 71.

[0230] The antigen-binding fragment of the anti-CD40L antibody and the antigen-binding fragment of the anti-CD28 antibody are as described above.

[0231]

[0232] In one example, the anti-CD40L / anti-CD28 bispecific antibody is

[0233] The anti-CD40L antibody or antigen-binding fragment thereof is an anti-CD40L scFv, or

[0234] The anti-CD28 antibody or antigen-binding fragment thereof is an anti-CD28 scFv, or

[0235] The anti-CD40L antibody or antigen-binding fragment thereof may be an anti-CD40L scFv, and the anti-CD28 antibody or antigen-binding fragment thereof may be an anti-CD28 scFv.

[0236] In one example, the anti-CD40L / anti-CD28 bispecific antibody may include an anti-CD40L antibody in scFv form and an anti-CD28 antibody in scFv form. The anti-CD40L scFv included in the bispecific antibody does not include an Fc region, and thus, compared to an existing anti-CD40L antibody including an Fc region, it can exhibit an equivalent or greater binding affinity for the CD40L antigen and an effect of inhibiting co-stimulatory molecules and inhibiting cytokine secretion, while not exhibiting thromboembolic side effects. In addition, since the anti-CD28 scFv included in the bispecific antibody is a monovalent antibody, it can achieve an advantageous effect of preventing T cell activation caused by CD28 dimer formation.

[0237] The bispecific antibody may comprise an anti-CD40L scFv and an anti-CD28 scFv, wherein the anti-CD40L scFv may be linked directly (e.g., without a peptide linker) or via a peptide linker to the N'-terminus, the C'-terminus, or both of the anti-CD28 scFv. The anti-CD28 scFv may be linked directly (e.g., without a peptide linker) or via a peptide linker to the N'-terminus, the C'-terminus, or both of the anti-CD40L scFv.

[0238] In one example, the anti-CD40L scFv or anti-CD28 scFv included in the bispecific antibody may include a heavy chain variable region and a light chain variable region in any order. For example, the scFv included in the bispecific antibody may include a light chain variable region and a heavy chain variable region in the N'-terminus to C'-terminus direction, and optionally include a peptide linker therebetween. Alternatively, the scFv included in the bispecific antibody may include a light chain variable region and a heavy chain variable region in the C'-terminus to N'-terminus direction, and optionally include a peptide linker therebetween.

[0239] The anti-CD40L scFv and anti-CD28 scFv of the above bispecific antibody may be linked via the constant region of the antibody.

[0240] The constant region of the antibody may refer to a constant region of a heavy chain (γ, δ, α, μ, or ε) or a light chain (λ, or κ) of an antibody (e.g., IgG, IgM, IgA IgG, or IgE). In one example, the constant region of the antibody may refer to a constant region (C kappa) of an IgG antibody light chain. In one example, the constant region of the antibody may comprise the amino acid sequence of SEQ ID NO: 95.

[0241] The constant region of the above antibody can be linked to the anti-CD40L scFv directly (e.g., without a peptide linker) or via a peptide linker.

[0242] The constant region of the above antibody can be linked to the anti-CD28 scFv directly (e.g., without a peptide linker) or via a peptide linker.

[0243] In one example, the bispecific antibody may comprise from the N'-terminus to the C'-terminus:

[0244] anti-CD40L scFv;

[0245] Optionally, a first peptide linker;

[0246] constant region of an antibody;

[0247] Optionally, a second peptide linker; and

[0248] Anti-CD28 scFv.

[0249] In one example, the bispecific antibody may comprise from the N'-terminus to the C'-terminus:

[0250] anti-CD28 scFv;

[0251] Optionally, a first peptide linker;

[0252] constant region of an antibody;

[0253] Optionally, a second peptide linker; and

[0254] Anti-CD40L scFv.

[0255] The first peptide linker and the second peptide linker may or may not be present independently in the bispecific antibody, and may be the same or different from each other.

[0256] In one example, the bispecific antibody may comprise the amino acid sequence of SEQ ID NO: 96 or 97.

[0257] The above bispecific antibody can achieve effects with significantly superior physical properties (e.g., thermal stability) compared to existing bispecific antibodies. For example, the bispecific antibody can maintain excellent binding affinity to antigens even after prolonged exposure to high temperatures, and exhibit excellent co-stimulatory molecule inhibition and cytokine secretion inhibition effects.

[0258]

[0259] Production of polynucleotides, recombinant vectors and antibodies

[0260] Another aspect provides a polynucleotide encoding the anti-CD40L / anti-CD28 bispecific antibody, the anti-CD40L antibody or antigen-binding fragment thereof, and / or the anti-CD28 antibody or antigen-binding fragment thereof.

[0261] Another aspect provides a recombinant vector comprising a polynucleotide. For example, the recombinant cell may be a cell transfected with the recombinant vector.

[0262] Another aspect provides a method for producing the anti-CD40L / anti-CD28 bispecific antibody, the anti-CD40L antibody or antigen-binding fragment thereof, and / or the anti-CD28 antibody or antigen-binding fragment thereof, comprising a step of expressing the polynucleotide in a cell. The step of expressing the polynucleotide can be performed by culturing a cell comprising the polynucleotide (e.g., in a recombinant vector) under conditions that permit expression of the polynucleotide. The method can further comprise a step of isolating and / or purifying the antibody or antigen-binding fragment thereof from the cell culture after the step of expressing or culturing.

[0263] The term "vector" may refer to a means for expressing a target gene in a host cell, as exemplified by viral vectors such as plasmid vectors, cosmid vectors, and bacteriophage vectors, adenovirus vectors, retrovirus vectors, and adeno-associated virus vectors. The recombinant vector may be composed of plasmids commonly used in the art (e.g., pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8 / 9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pIJ61, pLAFR1, pET series, and pUC19), phages (e.g., λgt4λB, λ-Charon, λΔz1, and M13), or engineered viruses (e.g., SV40, etc.).

[0264] In a recombinant vector, a polynucleotide may be operably linked to a promoter. The term "operably linked" refers to a functional linkage between a nucleotide sequence of interest and an expression control sequence (e.g., a promoter sequence). When "operably linked," the control element can control the transcription and / or translation of the nucleotide of interest.

[0265] Recombinant vectors can typically be constructed as cloning vectors or expression vectors. For recombinant expression vectors, any vector commonly available in the art can be used to express foreign proteins in plant, animal, or microbial cells. Various methods well known in the art can be used to construct recombinant vectors.

[0266] Recombinant vectors can be constructed accordingly for use in hosts such as prokaryotic or eukaryotic cells. For example, when the vector is constructed as an expression vector for use in a prokaryotic host, the vector typically may include a strong promoter for transcription (e.g., pLκλ promoter, CMV promoter, trp promoter, lac promoter, tac promoter, T7 promoter, etc.), a ribosome binding site for translation initiation, and a transcription / translation terminator sequence. On the other hand, an expression vector for use in a eukaryotic host may include a replication origin operable in eukaryotic cells, such as, but not limited to, the f1 replication origin, the SV40 replication origin, the pMB1 replication origin, the adeno-replication origin, the AAV replication origin, and the BBV replication origin. Additionally, the expression vector may typically comprise a promoter derived from the genome of a mammalian cell (e.g., a metallothionein promoter) or a promoter derived from a mammalian virus (e.g., an adenovirus late promoter, a vaccinia virus 7.5K promoter, an SV40 promoter, a cytomegalovirus promoter, and a tk promoter of HSV), and a polyadenylation sequence as a transcription termination sequence.

[0267] Recombinant cells can be produced by introducing a recombinant vector into a suitable host cell. Any host cell known in the art can be used in the present invention, as long as it can sequentially clone and stably express the recombinant vector. Examples of prokaryotic host cells usable in the present invention include Bacillus spp., such as E. coli, Bacillus subtilis, and Bacillus thuringiensis, and enterobacterial strains, such as Salmonella typhimurium, Serratia marcescens, and various Pseudomonas species. Eukaryotic host cells that can be used for transformation include, but are not limited to, Saccharomyce cerevisiae, insect cells and animal cells, such as Sp2 / 0, CHO (Chinese hamster ovary) K1, CHO DG44, PER.C6, W138, BHK, COS-7, 293, HepG2, Huh7, 3T3, RIN and MDCK.

[0268] Polynucleotides or recombinant vectors containing them can be introduced (transfected) into host cells using methods known in the art. For example, if the host cell is a prokaryotic cell, transfection can be performed using CaCl2 or electroporation. For eukaryotic host cells, gene introduction can be achieved using, but is not limited to, microinjection, calcium phosphate precipitation, electroporation, liposome-mediated transfection, or particle bombardment.

[0269] To select transformed host cells, a phenotype associated with a selectable marker can be utilized, using methods well known in the art. For example, if the selectable marker is a gene that confers resistance to a specific antibiotic, the host cells can be grown in a medium in the presence of the antibiotic to select for transformants of interest.

[0270] Another aspect provides a method for producing a bispecific antibody, comprising expressing a polynucleotide or a recombinant vector in a host cell. In one embodiment, the method may comprise culturing a recombinant cell containing the polynucleotide or the recombinant vector therein, and optionally isolating and / or purifying the antibody from the culture medium.

[0271]

[0272] Medicinal uses

[0273] In another aspect, a pharmaceutical use of the anti-CD40L antibody, the anti-CD28 antibody, or the anti-CD40L / anti-CD28 bispecific antibody is provided for the prevention, improvement, or treatment of one or more autoimmune diseases and graft-versus-host diseases selected from the group consisting of autoimmune diseases and graft-versus-host diseases.

[0274] More specifically, the present application provides a pharmaceutical composition for the prevention, improvement, or treatment of at least one autoimmune disease and graft-versus-host disease, comprising the anti-CD40L antibody, the anti-CD28 antibody, or the anti-CD40L / anti-CD28 bispecific antibody as an active ingredient. The pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.

[0275] Another aspect provides a use of the anti-CD40L / anti-CD28 bispecific antibody, the anti-CD40L antibody or antigen-binding fragment thereof, and / or the anti-CD28 antibody or antigen-binding fragment thereof for the prevention, improvement or treatment of one or more selected from the group consisting of autoimmune diseases and graft-versus-host diseases.

[0276] Another aspect provides the use of the anti-CD40L / anti-CD28 bispecific antibody, the anti-CD40L antibody or antigen-binding fragment thereof, and / or the anti-CD28 antibody or antigen-binding fragment thereof in the manufacture of a pharmaceutical composition for the prevention, improvement or treatment of one or more diseases selected from the group consisting of autoimmune diseases and graft-versus-host diseases.

[0277] Another aspect provides a method for preventing, improving or treating at least one autoimmune disease and graft-versus-host disease, comprising administering to a subject in need of prevention, improvement or treatment at least one autoimmune disease and graft-versus-host disease, the method comprising administering the anti-CD40L / anti-CD28 bispecific antibody, the anti-CD40L antibody or antigen-binding fragment thereof, and / or the anti-CD28 antibody or antigen-binding fragment thereof. The method may further comprise, prior to the administering step, a step of identifying a subject in need of prevention, improvement or treatment at least one autoimmune disease and graft-versus-host disease.

[0278] In the present application, "prevention" means any act of inhibiting or delaying the onset of a disease (illness) by administering a composition according to an example, "treatment" means any act of improving or beneficially changing the symptoms of a subject suspected of or affected by a disease by administering a composition according to an example, and "improvement" may mean any act of at least reducing the severity of symptoms, for example, a parameter related to a state in which a disease is treated, by administering a composition according to an example. The disease may mean an autoimmune disease and / or graft-versus-host disease.

[0279] In one example, the autoimmune disease and / or graft-versus-host disease may be due to overexpression and / or overactivation of T cells.

[0280] The above autoimmune diseases include rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes, Crohn's disease, scleroderma, Sjogren's syndrome, psoriasis, inflammatory bowel disease, ulcerative colitis, ankylosing spondylitis, interstitial lung disease, uveitis, optic neuritis, peripheral neuropathies, sarcoidosis, antiphospholipid syndrome, inflammatory myopathies, Behcet's disease, It may be at least one selected from the group consisting of, but is not limited to, alopecia totalis / universalis, pemphigus vulgaris, myasthenia gravis, Graves' disease, Hashimoto's thyroiditis, Guillain-Barre syndrome, celiac disease, and pernicious anemia.

[0281] The above graft-versus-host disease (GVHD) may be at least one selected from the group consisting of acute graft-versus-host disease and chronic graft-versus-host disease, but is not limited thereto.

[0282]

[0283] The pharmaceutical composition may further comprise a pharmaceutically acceptable carrier, diluent, and / or excipient. The pharmaceutically acceptable carrier, diluent, and / or excipient may be any selected from those commonly used in the formulation of antibodies. For example, pharmaceutically acceptable carriers include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

[0284] The above pharmaceutical composition may further include at least one selected from the group consisting of a lubricant, a humectant, a sweetener, a flavor enhancer, an emulsifier, a suspending agent, a preservative, etc.

[0285] The pharmaceutical composition may be administered to a subject orally or parenterally. Parenteral administration may include intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intrapulmonary administration, or rectal administration. Since oral administration leads to digestion of proteins or peptides, the active ingredient of the composition for oral administration may be coated or formulated to prevent digestion in the stomach. Additionally, the pharmaceutical composition may be administered using any device that allows the active ingredient to be delivered to target cells.

[0286] The term "pharmaceutically effective amount" as used herein may mean an amount of the active ingredient (the anti-CD40L / anti-CD28 bispecific antibody, anti-CD40L antibody and / or anti-CD28 antibody) that can exert a pharmaceutically significant effect in the prevention, improvement or treatment of autoimmune diseases and / or graft-versus-host diseases. The pharmaceutically effective amount of the antibody, or the appropriate dosage of the pharmaceutical composition expressed as the amount of the antibody, may be prescribed in various ways depending on various factors such as age, body weight, sex, pathological condition, diet, excretion rate, patient's reaction sensitivity, formulation type, administration time, administration route, and administration method. For example, the pharmaceutically effective amount of the antibody or the appropriate dosage of the pharmaceutical composition may be about 0.001 to about 1000 mg (amount of antibody) / kg (body weight) per day for adults, about 0.01 to about 100 mg, or 0.1 to 50 mg / kg.

[0287] As used herein, the pharmaceutical effective amount refers to the content or dosage of an effective ingredient capable of achieving a desired effect. The effective ingredient may be the anti-CD40L / anti-CD28 bispecific antibody, anti-CD40L antibody, and / or anti-CD28 antibody. The content or dosage of the effective ingredient in the pharmaceutical composition may vary depending on factors such as the formulation method, administration method, patient age, weight, sex, pathological condition, food, administration time, administration interval, administration route, excretion rate, and response sensitivity. For example, when the active ingredient is an antibody, a single dose may range from 0.001 to 1000 mg / kg, 0.01 to 100 mg / kg, 0.01 to 50 mg / kg, 0.01 to 20 mg / kg, 0.01 to 10 mg / kg, 0.01 to 5 mg / kg, 0.1 to 100 mg / kg, 0.1 to 50 mg / kg, 0.1 to 20 mg / kg, 0.1 to 10 mg / kg, 0.1 to 5 mg / kg, 1 to 100 mg / kg, 1 to 50 mg / kg, 1 to 20 mg / kg, 1 to 10 mg / kg, or 1 to 5 mg / kg, but is not limited thereto.

[0288] In one example, the pharmaceutical composition may be administered to the subject once a day or in divided doses of two or more times a day, and in one example, may be administered at intervals of 1 hour, 2 hours, 6 hours, 12 hours, 24 hours, 2 days, 3 days, 1 week, 2 weeks, 1 month, and / or 3 months.

[0289] The above dosage and / or administration cycle do not limit the scope of the present application in any way.

[0290] In another example, the content of the active ingredient in the pharmaceutical composition is, based on the total weight of the pharmaceutical composition, 0.01 wt% to 99.9 wt%, 0.01 wt% to 90 wt%, 0.01 wt% to 80 wt%, 0.01 wt% to 70 wt%, 0.01 wt% to 60 wt%, 0.01 wt% to 50 wt%, 0.01 wt% to 40 wt%, 0.01 wt% to 30 wt%, 1 wt% to 99.9 wt%, 1 wt% to 90 wt%, 1 wt% to 80 wt%, 1 wt% to 70 wt%, 1 wt% to 60 wt%, 1 wt% to 50 wt%, 1 wt% to 40 wt%, 1 wt% to 30 wt%, 5 wt% to 99.9 wt%, 5 wt% to It may be, but is not limited to, 90 wt%, 5 wt% to 80 wt%, 5 wt% to 70 wt%, 5 wt% to 60 wt%, 5 wt% to 50 wt%, 5 wt% to 40 wt%, 5 wt% to 30 wt%, 10 wt% to 99.9 wt%, 10 wt% to 90 wt%, 10 wt% to 80 wt%, 10 wt% to 70 wt%, 10 wt% to 60 wt%, 10 wt% to 50 wt%, 10 wt% to 40 wt%, or 10 wt% to 30 wt%.

[0291] In addition, the pharmaceutical composition may further include a pharmaceutically acceptable carrier and / or adjuvant in addition to the active ingredient. The pharmaceutically acceptable carrier is one commonly used in the formulation of drugs containing proteins, nucleic acids, or cells, and may refer to a carrier that does not stimulate a living organism and does not inhibit the biological activity and / or properties of the active ingredient. In one example, the carrier may be at least one selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like, but is not limited thereto. The above pharmaceutical composition may further include at least one selected from the group consisting of diluents, excipients, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc., which are commonly used in the manufacture of pharmaceutical compositions.

[0292] In one example, the pharmaceutically acceptable carrier is one commonly used in formulations, and includes, but is not limited to, saline solution, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, liposomes, etc., and may further include other conventional additives such as antioxidants and buffers as needed. In addition, diluents, dispersants, surfactants, binders, lubricants, etc. may be additionally added to formulate the composition into an injectable formulation such as an aqueous solution, suspension, emulsion, pills, capsules, granules, or tablets. Regarding suitable pharmaceutically acceptable carriers and formulations, each ingredient can be preferably formulated using the method disclosed in Remington's Pharmaceutical Sciences (19th edition, 1995). In one embodiment, the pharmaceutical composition may include a pharmaceutically acceptable carrier, such as a binder such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin; an excipient such as dicalcium phosphate; a disintegrant such as corn starch or sweet potato starch; a lubricant such as magnesium stearate, calcium stearate, sodium stearyl fumarate or polyethylene glycol wax; a sweetener; a flavoring agent; a syrup; a liquid carrier such as a fatty oil; a sterile aqueous solution; an injectable ester such as propylene glycol; polyethylene glycol; ethyl oleate; a suspending agent; an emulsion; a freeze-dried preparation; an external preparation; a stabilizer; a buffering agent; an animal oil; a vegetable oil; a wax; paraffin; a starch; tragacanth; a cellulose derivative; a polyethylene glycol; a silicone; a bentonite; a silica; talc; a zinc oxide, or a suitable combination thereof.

[0293] The subject of administration of the pharmaceutical composition provided herein may be a mammal including a human, a dog, a cat, a horse, a cow, a pig, a goat, a rabbit, a mouse, a rat, etc., or a cell, tissue, or culture thereof isolated therefrom. In one example, the subject may be an individual (a mammal such as a human) in need of prevention, improvement, and / or treatment of an autoimmune disease and / or graft-versus-host disease as described above, or a cell, tissue, or culture thereof isolated therefrom having an autoimmune disease and / or graft-versus-host disease.

[0294] The pharmaceutical composition may be administered orally or parenterally, or by contact with cells, tissues, or body fluids. Specifically, in the case of parenteral administration, it may be administered by subcutaneous injection, intramuscular injection, intravenous injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intrapulmonary administration, and rectal administration. When administered orally, since proteins or peptides are digested, the oral composition must be formulated to coat the active agent or protect it from degradation in the stomach. When administered intranasally, the pharmaceutical composition may be diluted and administered via nasal spray through a nebulizer or nebulizing system so that it is absorbed into the nasal cavity. Examples of nasal sprays or respiratory formulations for the nasal spray include aerosols.

[0295] In addition, the pharmaceutical composition may be formulated in the form of a solution, injection, suspension, syrup, emulsion, application agent, patch, extract, powder, granule, tablet, capsule, aerosol, etc. in an oil or aqueous medium, and may additionally include a dispersing agent or stabilizer for formulation.

[0296] In one embodiment, the pharmaceutical composition may be formulated as a troche, lozenge, tablet, aqueous suspension, oily suspension, prepared powder, granules, emulsion, hard capsule, soft capsule, syrup, or elixir. In another embodiment, the pharmaceutical composition may be formulated as an injection, a suppository, a powder for respiratory inhalation, an aerosol for spraying, an ointment, a powder for application, an oil, or a cream. In yet another embodiment, the pharmaceutical composition may be formulated as an injection. Specifically, a therapeutically effective amount of an antiviral peptide may be mixed with a stabilizer or a buffer in water to prepare a solution or suspension, which may be formulated for unit dose in ampoules or vials. In another embodiment, the pharmaceutical composition may be formulated as an aerosol by mixing a propellant or the like with additives to prepare a water-dispersed concentrate or a wet powder, and then formulated as an aerosol. In another embodiment, when the pharmaceutical composition is formulated for transdermal use, an ointment, cream, powder for application, oil, external skin preparation, etc. can be prepared by adding animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. as a carrier to a therapeutically effective amount of an antiviral peptide.

[0297]

[0298] The anti-CD40L / anti-CD28 bispecific antibody of the present application can exhibit excellent autoimmune disease and / or graft-versus-host disease therapeutic effects while preventing T cell activation effects by CD28 dimer formation and without exhibiting thromboembolic side effects, including anti-CD40L scFv and anti-CD28 scFv, and can exhibit excellent physical properties of a bispecific antibody.

[0299]

[0300] Figure 1 shows the genetic information of 49 clones that bind to human CD40L in enzyme-linked immunosorbent assay.

[0301] Figures 2a and 2b show that the 15 kinds of anti-CD40L antibodies expressed and purified above bind to the Jurkat D1.1 (hCD40L+) cell line expressing human CD40L, as confirmed by flow cytometry.

[0302] Figure 3 shows that the anti-CD40L antibodies (1G-2, 1F-7, 3B-7) bind to human CD40L recombinant protein and inhibit binding to Ragi (CD40L+) cell lines, as confirmed by flow cytometry.

[0303] Figure 4 shows the results of comparing the inhibitory ability of 17 anti-CD40L scFv antibodies to the positive control group (hu5C8 clone) on B cell costimulatory molecule expression, and confirming that the 1G-2 and 3F-9 clones showed superior inhibitory ability than the positive control group.

[0304] Figure 5 shows that when the dose-response (5 or 10 μg / ml) of the anti-CD40L antibody (1G-2) among 17 clones was confirmed, it showed an inhibitory effect similar to that of the positive control group.

[0305] Figure 6 shows that when treated with a high concentration (5 μg / ml) of anti-CD40L antibody (1G-2), B cell division inhibition ability of more than 50% was observed.

[0306] Figure 7 confirms that the anti-CD40L antibody (1G-2) significantly reduces antibody production in a concentration-dependent manner.

[0307] Figure 8 confirms that the expression of costimulatory molecules decreases as the concentration of anti-CD40L antibody (1G-2) increases.

[0308] Figure 9 confirms that the production of IL-12 by dendritic cells is effectively inhibited by treatment with anti-CD40L antibody (1G-2).

[0309] Figure 10 shows the results of measuring the antigen binding affinity of the 1G-2 clone.

[0310] Figure 11 shows the results of comparing the co-stimulatory molecule inhibitory ability of 15 anti-CD40L scFv antibodies on Daudi cells with the positive control group (hu5C8), and confirming that the 1H-8 and 3E-3 clones exhibited inhibitory ability similar to the positive control group.

[0311] Figure 12 shows the T cell epitope content evaluated using an immunoinformatics tool through in silico antibody sequence analysis from Abzena, UK, for immunogenicity analysis of selected chicken-derived anti-CD40L antibodies (1G-2, 1H-8, 3E-3).

[0312] Figures 13a to 13c show the genetic information obtained through base sequence analysis of 41, 40, and 38 clones, respectively, that showed higher affinity than the existing wild-type antibody clones during the non-immunization process of antibodies (1G-2, 1H-8, and 3E-3).

[0313] Figure 14 shows that the recombinant antibody was purified from the cell culture using affinity chromatography after overexpressing the antibody through human embryonic kidney (HEK293F) cell transformation.

[0314] Figure 15 shows that the three anti-CD40L antibodies (3E-3 clone and non-immunized 2E9F clone and 2E9F VH G49S clone) bind to Jurkat D1.1 (hCD40L+) cell line expressing human CD40L, as confirmed by flow cytometry.

[0315] Figure 16 shows that the three types of anti-CD40L antibodies bind to human CD40L (a recombinant protein in the form of hCD40L-Isoleucine zipper-Hemagglutinin) as confirmed by enzyme-linked immunosorbent assay.

[0316] Figures 17a and 17b confirm that both the 2E9F clone and the 2E9F VH G49S clone inhibit CD40 / CD40L interaction.

[0317] Figure 18 shows the genetic information of 79 clones selected from the humanization process of the 3E-3 clone that showed higher affinity than the existing wild-type antibody clone, obtained through base sequence analysis.

[0318] Figure 19 shows the alignment results of the humanized sequence of the framework region and the acquired clone sequence number 91.

[0319] Figure 20 shows eight clone combinations containing human and chicken-derived residues cloned into a phagemid vector.

[0320] Figure 21 shows that eight combinations of clones showed binding ability to human CD40L recombinant protein in phage enzyme immunoassay.

[0321] Figure 22 shows that eight types of expressed and purified antibody clones bind to L cell lines overexpressing human CD40L, as confirmed by flow cytometry.

[0322] Figure 23 shows that among the eight clones manufactured above (LSS, LSG, LIS, LIG, TSS, TSG, TIS, TIG clones), the binding inhibition ability of the TSS, TSG, TIS, and TIG clones was superior.

[0323] Figure 24 shows the results of confirming the inhibition ability of the expression of B cell costimulatory molecules (CD80, CD86) by the TSS, TSG, TIS, and TIG clones at different concentrations (2, 4, 6, 8, 10 μg / ml), and confirming that the TSG clone had the highest inhibition ability of the expression of B cell costimulatory molecules.

[0324] Figure 25 shows a schematic diagram of bond strength measurement using Biacore.

[0325] Figures 26a and 26b show the results of measuring CD40L binding affinity using the multi-kinetics method and the single kinetics method.

[0326] Figure 27 shows the selection of 49 clones that bind to human CD28 and the analysis of their genetic information.

[0327] Figure 28 confirms that 12 kinds of expressed and purified anti-CD28 antibodies bind to the Jurkat E6.1 (Human CD28+) cell line.

[0328] Figure 29 shows the results of confirming the inhibitory ability of 12 types of anti-CD28 antibodies to inhibit IL-2 secretion in Jurkat E6.1 cell lines, and confirming that the J6-2 and J6-3 clones exhibited inhibitory ability similar to that of the positive control group.

[0329] Figure 30 shows that among 12 types of anti-CD28 antibodies, the J6-3 clone showed higher IL-2 inhibition ability than the positive control group (FR104) and showed similar IFN gamma secretion inhibition ability to the positive control group.

[0330] Figure 31 shows that in the case of cells treated with the J6-3 clone, the binding affinity of CD80 / CD86 proteins is significantly reduced compared to cells not treated with the J6-3 clone.

[0331] Figure 32 confirms that clones 4-25, 6-15, and 6-23 bind similarly to the positive control (FR104).

[0332] Figure 33 shows the immunogenicity analysis using in silico antibody analysis by Abzena, UK, to confirm the immunogenicity of the J6-3 clone.

[0333] Figure 34 is a schematic diagram for comparing the human germline sequence with the highest homology to the J6-3 clone for de-immunization and simultaneous humanization.

[0334] Figure 35 shows the base sequence analysis of various genetic information binding to human CD28 in enzyme immunoassay.

[0335] Figure 36 shows that clone number 95 (G12 clone) was finally obtained through base sequence analysis following enzyme immunoassay.

[0336] Figure 37 shows the results of the analysis of the G12 clone, confirming the presence of two immunogenic sites.

[0337] Figure 38 shows the establishment of a final clone with completed immunogenicity and humanization of the existing J6-3 clone.

[0338] Figure 39 shows the expression and purified anti-CD28 antibodies (J6-3 clone and humanized 2-G12 clone) on Jurkat E6.1 (hCD28 + ) was confirmed to bind to cell lines using flow cytometry.

[0339] Figure 40 shows that the J6-3 clone and the humanized 2-G12 clone bind to human CD28 recombinant protein (hCD28) as confirmed by enzyme-linked immunosorbent assay.

[0340] Figure 41 shows the results of confirming the cytokine secretion inhibition ability of CD4 T cells of the humanized 2-G12 clone, and confirming that the 2-G12 clone exhibited a superior IL-2 (interleukin-2) secretion inhibition ability than the positive control group (FR104) and an IFN gamma inhibition ability similar to the positive control group (FR104).

[0341] Figure 42 shows a schematic diagram of the TSG clone, a humanized anti-CD40L scFv antibody prepared in Example 1-4, and the 2-G12 antibody, a humanized anti-CD28 scFv antibody prepared in Example 2-3, cloned into a bispecific antibody form containing a Ck linking domain and then expressed in a mammalian expression system.

[0342] Figure 43 shows that the recombinant antibody was successfully purified from the cell culture using affinity chromatography after overexpressing the antibody through human embryonic kidney (HEK293F) cell transformation.

[0343] Figure 44 shows the successful purification of the bispecific antibody (TSGxHu2G12 clone) prepared in Example 3.2.1.

[0344] Figure 45 is a graph showing that the bispecific antibody (TSGxHu2G12 clone) exhibits CD28 binding affinity equivalent to that of TSGx2-G12 and CD28.

[0345] Figure 46 is a graph showing that the bispecific antibody (TSGxHu2G12 clone) exhibits binding affinity to cell surface CD28 at a level equivalent to that of TSGx2-G12 and CD28.

[0346] Figure 47 shows a schematic diagram of an experiment to confirm the CD28-CD80 interaction inhibition ability of Example 3.2.4.

[0347] Figure 48 is a graph showing that a bispecific antibody (TSGxHu2G12) comprising the Hu2G12 clone inhibits binding of recombinant CD80 protein at 1000 nM antibody concentration to a similar extent as a bispecific antibody (TSGx2-G12) comprising the 2-G12 clone.

[0348] Figure 49 shows the light chain (V) of six anti-CD40L / anti-CD28 bispecific antibodies manufactured by performing an additional humanization process in Example 3-3. L) and a clone introducing the S42Q mutation into the heavy chain (V H ) is a graph showing that the clone (TSGxHu2G12-S76N) introducing the S76N mutation exhibits binding affinity to CD28 equivalent to that of the anti-CD40L / anti-CD28 bispecific antibody (TSGx2-G12, Table 16) prepared in Example 3-1.

[0349] Figure 50 is a graph showing that the TSGxHu2G12-S42Q and TSGxHu2G12-S76N clones have equivalent binding affinity to cell surface CD28 compared to the TSGx2-G12 clone.

[0350] Figure 51 shows a schematic diagram of an experiment to confirm the CD28-CD80 interaction inhibition ability of Example 3.3.4.

[0351] Figure 52 is a graph showing that the TSGxHu2G12-S42Q and TSGxHu2G12-S76N clones exhibit recombinant CD80 protein binding inhibition ability to an equivalent degree as the TSGx2-G12 clone.

[0352] Figure 53 is a schematic diagram showing a positive feedback mechanism in which activated T cells activate APCs, which in turn increase the activity of T cells.

[0353] Figure 54 shows a schematic diagram of the experimental process of Example 3-4.

[0354] Figure 55 is a graph showing that the dual antibody (TSGx2-G12) and the CD28 single inhibitory antibody (aCot-Ck-aCD28; aCot-Ck-2-G12) exhibit an IFNr inhibitory effect.

[0355] Figure 56 is a schematic diagram showing a phenomenon in which, when an autoantigen-specific T cell recognizes an autoantigen presented by an antigen-presenting cell and receives a TCR signal (signal 1), it is not activated even if it receives autoantigen stimulation again later if it does not receive co-stimulation (signal 2) from the antigen-presenting cell.

[0356] Figure 57 shows a schematic diagram of the experimental process of Example 3-5.

[0357] Figure 58 shows the experimental results confirming that the amount of IFNr was significantly reduced in the group treated with anti-CD40L / anti-CD28 bispecific antibodies compared to the negative control group, and that CD4 T cells treated with bispecific antibodies did not respond even when re-stimulated with antigen.

[0358] Figure 59 is an experimental result showing that the anti-CD40L / anti-CD28 bispecific antibody of the present application has excellent T cell suppression ability regardless of the order of the anti-CD40L antibody and the anti-CD28 antibody.

[0359] Figure 60 shows a schematic diagram of the simultaneous suppression method and the individual suppression method.

[0360] Figures 61 and 62 are experimental results showing that CD40L and CD28 co-localized at the same location only in the group treated with the anti-CD40L-Ck-CD28 bispecific antibody, suggesting that the anti-CD40L / anti-CD28 bispecific antibody of the present application acts in a simultaneous inhibitory manner.

[0361] Figures 63 and 64 are experimental results suggesting that the anti-CD40L / anti-CD28 bispecific antibody of the present application acts in a simultaneous inhibitory manner, as the CD28-mNeonGreen fluorescence in the cell membrane region significantly changes only in the group treated with the anti-CD40L-Ck-CD28 bispecific antibody, and the FRET efficacy value has statistical significance compared to other groups.

[0362] Figures 65 and 66 show that the group treated with the anti-CD40L / anti-CD28 bispecific antibody did not show weight loss during the experimental period, and disease severity assessments confirmed that no disease developed. Furthermore, all mice survived during the experimental period, confirming that disease progression was completely suppressed only in the group treated with the bispecific antibody.

[0363] Figure 67 shows one exemplary form of the anti-CD40L / anti-CD28 bispecific antibody of the present application (anti-CD40L scFv - Ck - anti-CD28 scFv).

[0364] Figure 68 is a graph showing that the 1-1-H, 1-12C, 1-12-H, 2-12-C, and 3-11-C clones of mouse anti-CD40L antibodies that bind to mouse CD40L effectively bind to mouse CD40L expressed on the cell surface in a concentration-dependent manner.

[0365] Figure 69 is a graph showing that PV1x2-12-C antibody binds to activated mouse CD4 T cells, as measured by flow cytometry using a fluorescent anti-Ck antibody after binding PV1x2-12-C antibody to activated CD4 T cells.

[0366] Figure 70 is an experimental result showing that, similar to the experimental result of the anti-CD40L / anti-CD28 bispecific antibody that underwent the humanization process in Example 3, the anti-CD40L / anti-CD28 bispecific antibody for mice suppressed T cell activity by blocking the CD40L and CD28 signals of CD4 T cells.

[0367] Figure 71 is a graph showing that the bispecific antibody provided by the present application effectively suppresses autoimmune demyelinating disease, as confirmed by confirming that the clinical severity of the disease was significantly lower in the group (PV1x2-12-C) treated with the anti-CD40L / anti-CD28 bispecific antibody for mice.

[0368]

[0369] The present invention will be described in more detail below with reference to the following examples. However, these examples are provided solely to illustrate the present invention, and the scope of the present invention is not limited by these examples.

[0370]

[0371] Example 1. Anti-CD40L antibody

[0372] Example 1-1. Selection of chicken-derived anti-CD40L antibodies (Lead antibody)

[0373] An antibody library in the form of scFv was produced by immunizing chickens (Biopore, White leghorn chicken, 3) with human CD40L recombinant protein (R&D Systems, Minneapolis, MN, USA) using a previously reported method. The complexity of the three chicken antibody libraries produced was 2.4 x 10 9 , 2.4 x 10 9 , 2.7 x 10 9 Bio-panning for human CD40L was performed using a chicken antibody library, and 49 clones that bind to human CD40L were selected through enzyme-linked immunosorbent assay, and their genetic information was obtained through base sequence analysis (Fig. 1).

[0374] To produce 15 antibody clones that bind to human CD40L recombinant protein in the form of scFv-Ck-scFv-HIS-HA fusion proteins [anti-CD40L scFv antibody (N'-VL-linker (SEQ ID NO: 93)-VH-C') - Ck (SEQ ID NO: 95) - anti-cotinine scFv antibody (N'-VL-linker (SEQ ID NO: 93)-VH-C') - HIS-HA], they were cloned into an animal cell expression vector (pCEP4 vector, Invitrogen, Carlsbad, CA, USA), and after transforming human embryonic kidney (human embryonic kidney 293F, HEK293F) cells (Invitrogen, Carlsbad, CA, USA), the antibodies were purified from the cell culture medium by affinity chromatography.

[0375] In order to confirm the effect of the anti-CD40L antibody in the form of a bispecific antibody in which two monovalent antibodies are linked, the anti-CD40L scFv antibody was linked to an anti-cotinine scFv antibody that binds to cotinine, a substance that does not exist in the body, and the following experiment was performed. The anti-cotinine antibody was obtained from Korean Patent Publication No. 10-2019-0023084 A and used, and the CDR and variable region sequences of the anti-cotinine antibody are as shown in SEQ ID NOs: 120 to 126 and 127 to 128.

[0376] CloneTransfection volume (mL)Quantificationμgmg / L2E-5100100710.13E-11009319.33E-111009529.53C151006566.63A-11004674.73B-11003853.93H-71003893.91 B-51004564.61E-12100221222.11F-8100463246.31H-8100679267.92 B-11100185418.53C-7100148814.93E-3100503250.33F-9100108810.9

[0377] 1.1.1. Confirmation of binding to human CD40L

[0378] The binding of the 15 anti-CD40L antibodies expressed and purified above to the Jurkat D1.1 (hCD40L+) cell line (ATCC, Manassas, VA, USA) expressing human CD40L was confirmed by flow cytometry (Fig. 2a, Fig. 2b).

[0379] In addition, it was confirmed by flow cytometry that the anti-CD40L antibodies (1G-2, 1F-7, 3B-7) bind to human CD40L recombinant protein and inhibit its binding to Raji (CD40L+) cell line (ATCC, Manassas, VA, USA) (Fig. 3).

[0380]

[0381] 1.1.2. Inhibition of B cell and dendritic cell activity

[0382] CD40L, expressed on the surface of T cells, is known to bind to CD40 on the surface of antigen-presenting cells (APCs), such as B cells and dendritic cells, thereby activating them. Therefore, the ability of anti-CD40L antibodies to inhibit the activity of B cells and dendritic cells by inhibiting CD40L / CD40 interactions was evaluated.

[0383] To obtain human B cells and monocytes, leukapheresis was performed on healthy adults, and B cells and monocytes were separated from the obtained leukocytes using the MACS cell separation method (Miltenyi Biotec, 130-050-201). The monocytes were differentiated into dendritic cells using GM-CSF (Granulocyte-macrophage colony-stimulating factor) and IL-4 (interleukin 4).

[0384] A system was constructed in which CD40 stimulation is delivered to B cells and dendritic cells by co-culturing a mouse-derived fibroblast cell line (CD154L cells) expressing human CD40L (Sim et al. Arthritis Research & Therapy (2015) 17:190 DOI 10.1186 / s13075-015-0687-1) with B cells or dendritic cells, and it was confirmed whether the produced anti-CD40L antibody inhibits the activity of B cells or dendritic cells. At this time, CD154L cells were treated with 60 Gy of radiation to inhibit cell division, and as a positive control, a previously known anti-CD40L antibody (hu5C8 clone) (Karpusas et al. Structure of CD40 Ligand in Complex with the Fab Fragment of a Neutralizing Humanized Antibody Structure. 2001 Apr 4;9(4):321-9.) was expressed and purified in the form of scFv and used.

[0385]

[0386] After co-culturing B cells, CD154L cells, and anti-CD40L antibodies (5 μg / ml), the extent to which the increase in the expression of costimulatory molecules (CD80, CD86) due to B cell activation was inhibited by anti-CD40L antibodies was confirmed through flow cytometry, and the results are shown in Figures 4a to 4c (Figures 4b and 4c are quantitative representations of the results of Figure 4a).

[0387] As can be seen in the above Figures 4a, 4b, and 4c, the inhibition ability of B cell costimulatory molecule expression of 17 anti-CD40L scFv antibodies was compared with the positive control group (hu5C8 clone), and it was confirmed that the 1G-2 and 3F-9 clones showed superior inhibition ability than the positive control group (hu5C8) (Figure 4c).

[0388]

[0389] In addition, when the dose-response (5 or 10 μg / ml) of the anti-CD40L antibody (1G-2) among the 17 clones was confirmed, it showed an inhibitory effect similar to that of the positive control group (hu5C8) (Fig. 5).

[0390]

[0391] 1.1.3. Inhibition of B cell division

[0392] When B cells and CD154 L cells are co-cultured, CD40 of the B cells is stimulated and the B cells divide. At this time, the degree of cell division can be confirmed by treating the dividing cells with Edu and detecting it with an anti-Edu antibody.

[0393] In order to confirm the B cell division inhibition ability of the above anti-CD40L antibody (1G-2), Edu (Thermo Fisher scientific, C10637) was added to the co-culture system (culture solution of B cells, CD154L cells, and anti-CD40L antibody), and the amount of Edu incorporated into the DNA of dividing B cells was analyzed using a flow cytometer using an anti-Edu antibody (Thermo Fisher scientific, C10637), thereby measuring the degree of B cell division.

[0394]

[0395] As a result, when treated with a high concentration (5 μg / ml) of anti-CD40L antibody (1G-2), it was confirmed that B cell division inhibition ability was more than 50% (Fig. 6).

[0396]

[0397] 1.1.4. Inhibition of antibody production by B cells

[0398] When B cells and CD154 L cells are co-cultured, B cells secrete IgM upon CD40 stimulation, and the degree of B cell activation can be measured by measuring the amount of secreted IgM.

[0399] Accordingly, whether antibody production of B cells was inhibited when treated with the anti-CD40L antibody (1G-2) was confirmed through IgM ELISA, and the results are shown in Figure 7.

[0400]

[0401] As can be seen in Figure 7, it was confirmed that the anti-CD40L antibody (1G-2) significantly reduced the amount of antibody production in a concentration-dependent manner (Figure 7).

[0402]

[0403] 1.1.5. Inhibition of costimulatory molecule expression in dendritic cells

[0404] In addition to the inhibition of B cell activity by anti-CD40L antibodies, in order to verify the inhibition of dendritic cell (DC) activity, dendritic cells, CD154L cells, and anti-CD40L antibodies were cultured together, and the expression level of costimulatory molecules (CD80, CD86) of dendritic cells was confirmed through flow cytometry, and the results are shown in Figure 8.

[0405]

[0406] As can be seen in Figure 8, it was confirmed that the expression of costimulatory molecules (CD80, CD86) decreased as the concentration of anti-CD40L antibody (1G-2) increased (Figure 8).

[0407]

[0408] 1.1.6. Inhibition of cytokine secretion by dendritic cells

[0409] When dendritic cells and CD154 L cells are co-cultured, dendritic cells are activated by CD40 stimulation and cytokine production increases. Therefore, the degree of dendritic cell activation can be measured by measuring the amount of secreted cytokines.

[0410] To determine whether cytokine production of dendritic cells is inhibited when treated with anti-CD40L antibodies, the amount of IL-12 (interleukin-12) secreted into the supernatant of the co-culture system (culture solution of dendritic cells, CD154L cells, and anti-CD40L antibodies) was measured using IL-12 ELISA, and the results are shown in Figure 9.

[0411]

[0412] As can be seen in Figure 9, it was confirmed that the production of IL-12 was effectively inhibited by treatment with anti-CD40L antibody (1G-2) (Figure 9).

[0413]

[0414] 1.1.7. Confirmation of binding affinity to CD40L

[0415] Through the above examples 1.1.1 to 1.1.6, it was confirmed that the 1G-2 clone among the anti-CD40L antibodies could effectively inhibit the function of CD40L.

[0416]

[0417] To measure the binding affinity between the 1G-2 clone and CD40L protein, Biacore T200 (GE Healthcare) was used, and the measurement was performed by surface plasmon resonance (SPR) at 25℃. The binding affinity measurement using Biacore T200 was performed by injecting analyte onto the chip surface where the ligand was immobilized and going through the association, dissociation, and regeneration processes. The affinity measurement value was calculated using the 1:1 binding model of BIAevaluation software version 1.0, and the binding affinity measurement was performed by immobilizing the antibody on the surface of the CM5 chip. 2B1-Ck-1G2 and 1G2-Ck-COT 300 RU were immobilized on the chip surface at pH 4.5 and pH 5.0, respectively. The 2B1 was used as a partner antibody to confirm the effect of the 1G2 clone in the form of a bispecific antibody, similar to the anti-cotinine antibody. The binding strength was measured by diluting CD40L protein by half from 5 nM at a flow rate of 30 μl / min, with association / dissociation times of 3 minutes each. For each cycle, 10 mM Glycine pH 2.0 containing 500 mM NaCl was regenerated for 30 seconds at a flow rate of 30 μl / min.

[0418]

[0419] The results of measuring the binding affinity between the above 1G-2 clone and CD40L protein are shown in Figure 10. As a result of the binding affinity measurement, the KD value was measured to be 0.1 to 0.2 nM, indicating a high on rate (Figure 10).

[0420]

[0421] Example 1-2. Anti-CD40L antibody screening (backup antibody)

[0422] To further screen anti-CD40L antibodies with excellent B cell activation inhibitory ability, the B cell activation inhibitory ability of 15 antibodies with different complementarity determining region (CDR) sequences that bind to human CD40L recombinant protein was evaluated using a peripheral blood B lymphoma cell line (Daudi cell) expressing human CD40 (KCLB, Seoul, Republic of Korea) and a mouse fibroblast cell line (CD154L cell) expressing human CD40L.

[0423] After co-culturing the above Daudi cells, CD154L cells, and anti-CD40L antibody (2 μg / ml), the expression level of costimulatory molecules (CD80, CD86) of Daudi cells was confirmed through flow cytometry, and the results are shown in Figure 11.

[0424]

[0425] As a result of comparing the co-stimulatory molecule inhibitory ability of 15 anti-CD40L scFv antibodies on Daudi cells with that of the positive control group (hu5C8), it was confirmed that the 1H-8 and 3E-3 clones showed inhibitory ability similar to that of the positive control group (Fig. 11).

[0426]

[0427] By combining Examples 1-1 and 1-2, 1G-2, 1H-8, and 3E-3 clones were selected as anti-CD40L antibodies, and the CDR and variable region sequences of the antibodies are summarized in the table below:

[0428] [3E-3 Clone] Region sequence L-CDR1SGGYSSYGIYYYG (SEQ ID NO: 1) L-CDR2NGNKRPS (SEQ ID NO: 4) L-CDR3GSGDSSSDSGI (SEQ ID NO: 7) H-CDR1GFTFSSYGMN (SEQ ID NO: 10) H-CDR2AISNDGSSTSYAPAVKG (SEQ ID NO: 13) H-CDR3ESTNGGWVADDIDA (SEQ ID NO: 16) VLALTQPSSVSANLGGTVKITCSGGYSSYGIYYYGWYQQKSPGSAPVTLIYNGNKRPSNIPSRFSGSTSGSTNTLTITGVQVDDEAVYFCGSGDSSSDSGIFGAGTTLTVL (SEQ ID NO: 47) Linker GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93)VHAVTLDESGGGLQTPGGALSLVCKASGFTFSSYGMNWVRQAPGKGLEWVGAISNDGSSTSYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKESTNGGWVADDIDAWGHGTEVIVSS (SEQ ID NO: 51)

[0429] [1G-2 Clone] Region sequence L-CDR1SGDSSWYG (SEQ ID NO: 2) L-CDR2ANTNRPS (SEQ ID NO: 5) L-CDR3GSADSTYTAA (SEQ ID NO: 8) H-CDR1GFDFSSYDMN (SEQ ID NO: 11) H-CDR2GIYDDGSGTVYAPAVKG (SEQ ID NO: 14) H-CDR3GGGADNIDA (SEQ ID NO: 17) VLLTQASSVSANLGGTVEITCSGDSSWYGWYQQKSPGSAPVTLIYANTNRPSDIPSRFSGSTSGSTGTLTITGVQADDEAVYYCGSADSTYTAAFGAGTTLTVL (SEQ ID NO: 49) Linker GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93)VHAVTLDESGGGLQTPGGTLSLVCKASGFDFSSYDMNWVRQAPGKGLEYVAGIYDDGSGTVYAPAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCTRGGGADNIDAWGHGTEVIVSS (SEQ ID NO: 56)

[0430] [1H-8 Clone] Region sequence L-CDR1SGGSGSYG (SEQ ID NO: 3) L-CDR2WDDERPS (SEQ ID NO: 6) L-CDR3GGYDDSSYAGI (SEQ ID NO: 9) H-CDR1GFTFSSYGMQ (SEQ ID NO: 12) H-CDR2AIDDDGSSTNYGAAVKG (SEQ ID NO: 15) H-CDR3DGIIYYWNADAGYIDA (SEQ ID NO: 18) VLLTQPSSVSANPGETVKITCSGGSGSYGWYQQKSPGSAPVTLIYWDDERPSDIPSRFSGSKSGSTATLTITGVQAEDEAVYFCGGYDDSSYAGIFGAGTTLTVL (SEQ ID NO: 50) Linker GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93)VHAVTLDESGGGLHTPGGALSLVCKASGFTFSSYGMQWVRQAPGKGLEFVAAIDDDGSSTNYGAAVKGRATISRDNGQSTVRLQLNNLRAEDTGTYYCAKDGIIYYWNADAGYIDAWGHGTEVIVSS (SEQ ID NO: 57)

[0431] In the above table, the CDR sequences (L-CDR1, L-CDR2, L-CDR3, H-CDR1, H-CDR2, H-CDR3) included in the light chain variable region and heavy chain variable region are underlined.

[0432]

[0433] Example 1-3. Non-immunization of antibodies

[0434] Antibodies selected from animal immune libraries have the potential to be immunogenic when administered to humans, so the antibodies were optimized to have low immunogenicity and high affinity for the target antigen. To analyze the immunogenicity of the selected chicken-derived anti-CD40L antibodies (1G-2, 1H-8, 3E-3), the T cell epitope content was assessed using an immunoinformatics tool through in silico antibody sequence analysis from Abzena, UK (Figure 12). To select antibodies with low immunogenicity in humans and high affinity for CD40L, a mutant non-immunogenic antibody library was constructed by substituting highly immunogenic regions in the antibody sequence with human germline amino acids.

[0435] The complexity of the three non-immunogenic antibody libraries (1G-2, 1H-8, 3E-3) produced was 5.4 x 10 8 , 4.3 x 10 9 , 2.6 x 10 8 Bio-panning was performed on the human CD40L recombinant protein from the produced non-immunogenic antibody library, and 52, 50, and 54 clones binding to the human CD40L recombinant protein were secured through enzyme-linked immunosorbent assay, and 41, 40, and 38 clones showing higher affinity than the existing wild-type antibody clones were selected, and their genetic information was secured through base sequence analysis (Figures 13a to 13c).

[0436] Among the candidate antibodies, 2E9F derived from the 3E-3 clone had 15 of the 16 immunogenic residues substituted with residues identical to human germline amino acids, and the unsubstituted V H A non-immunogenic antibody gene was synthesized by introducing serine, which is identical to the human germline amino acid, at amino acid residue G49. The selected non-immunogenic antibodies 2E9F and 2E9F VH G49S was cloned into the corresponding mammalian cell expression vector for expression in the scFv-Ck-scFv format. The antibody was overexpressed through human embryonic kidney 293F (HEK293F) cell transformation, and the recombinant antibody was purified from the cell culture using affinity chromatography (Fig. 14).

[0437]

[0438] 1.3.1. Confirmation of binding to human CD40L

[0439] The binding of the above three anti-CD40L antibodies (3E-3 clone and non-immunized 2E9F clone and 2E9F VH G49S clone) to Jurkat D1.1 (hCD40L+) cell line expressing human CD40L was confirmed by flow cytometry (Fig. 15).

[0440]

[0441] In addition, the binding of the above three anti-CD40L antibodies to human CD40L (recombinant protein in the form of hCD40L-Isoleucine zipper-Hemagglutinin) (R&D Systems, Minneapolis, MN, USA) was confirmed by enzyme-linked immunosorbent assay (Fig. 16).

[0442]

[0443] 1.3.2. CD40 / CD40L binding inhibition ability

[0444] The non-immunized 2E9F clone and 2E9F VH G49S clone were treated with Jurkat D1.1 (hCD40L+) cell line or CD154L (hCD40L+) cell line, and then treated with CD40 antigen and analyzed by flow cytometry. As a result, it was confirmed that both the 2E9F clone and the 2E9F VH G49S clone inhibited CD40 / CD40L interaction (Fig. 17a and Fig. 17b).

[0445]

[0446] The anti-CD40L antibodies (1G-2, 1H-8) selected in Example 1-2 were also de-immunized using the same method as above.

[0447]

[0448] Example 1-4. Humanization of antibodies

[0449] To improve antibody safety, humanization was performed by replacing the framework region of a chicken-derived anti-CD40L antibody, excluding the complementarity determining region (CDR), with the human germline sequence. Simultaneously with antibody humanization, a Trimer controlled library (GENEWIZ, NJ, USA) method was used to generate a mutant antibody library containing both human germline amino acids and the amino acid sequence of the original antibody to select antibodies with high affinity for CD40L.

[0450] To further humanize the remaining 10 chicken-derived residues in the 3E-3 clone, a second humanization library was constructed using the Trimer controlled library provided by GENEWIZ, and the complexity of the constructed humanization library was 5.0 X 10 8 The total number of amino acid residues that needed to be substituted was 31. Bio-panning was performed on human CD40L recombinant protein from the constructed humanized antibody library, and a total of 87 clones that bound to human CD40L recombinant protein were secured through enzyme-linked immunosorbent assay. 79 clones showing higher affinity than the existing wild-type antibody clones were selected, and their genetic information was secured through base sequence analysis (Fig. 18).

[0451]

[0452] As a result, clone number 91 was obtained in which 28 of the 31 residues were substituted identically to the human germline amino acid sequence.

[0453]

[0454] Figure 19 shows the alignment results of the humanized sequence of the framework region and the acquired clone sequence number 91. Using the acquired clones, polymerase chain reaction was performed to generate eight clone combinations, each containing human and chicken-derived residues (the three chicken-derived residues are highlighted in red in Figure 19), which were then cloned into a phagemid vector (Figure 20).

[0455]

[0456] The three non-humanized chicken-derived residues correspond to the 12th residue from the N'terminus of the L-FR2 region (humanized sequence: L, sequence of clone 91: T), the 21st residue from the N'terminus of the H-FR1 region (humanized sequence: S, sequence of clone 91: I), and the 14th residue from the N'terminus of the H-FR2 region (humanized sequence: S, sequence of clone 91: G). Eight clones were named LSS, LSG, LIS, LIG, TSS, TSG, TIS, and TIG by combining the possible cases. For example, the "LSS" clone is a clone in which the 12th residue from the N'terminus of the L-FR2 region corresponds to "L", the 21st residue from the N'terminus of the H-FR1 region corresponds to "S", and the 14th residue from the N'terminus of the H-FR2 region corresponds to "S".

[0457]

[0458] 1.4.1. Confirmation of binding to human CD40L

[0459] Phage enzyme-linked immunosorbent assay was performed with eight clones (LSS, LSG, LIS, LIG, TSS, TSG, TIS, TIG clones) for which cloning was completed, and the results confirmed that all combinations of clones showed binding ability to human CD40L recombinant protein in the phage enzyme-linked immunosorbent assay (Fig. 21).

[0460]

[0461] 1.4.2. Confirmation of binding to L cell line

[0462] Eight types of humanized antibody clones that showed binding ability to human CD40L recombinant protein in phage enzyme-linked immunosorbent assay were cloned into the corresponding mammalian cell expression vector to express them in the form of scFv-Ck-scFv. After overexpression of the antibodies through human embryonic kidney 293F (HEK293F) cell transformation, the recombinant antibodies were purified from the cell culture medium using affinity chromatography. The binding of the eight types of expressed and purified antibody clones to the L cell line overexpressing human CD40L was confirmed through flow cytometry (Fig. 22).

[0463]

[0464] 1.4.3. Confirmation of binding inhibition of human CD40 and L cell lines

[0465] Flow cytometry was performed to determine whether the anti-CD40L antibody inhibits binding to human CD40 protein and L cell lines overexpressing hCD40L.

[0466]

[0467] Among the eight clones manufactured above (LSS, LSG, LIS, LIG, TSS, TSG, TIS, TIG clones), it was confirmed that the binding inhibition ability of the TSS, TSG, TIS, and TIG clones was superior (Fig. 23).

[0468]

[0469] 1.4.4. Confirmation of inhibition of B cell costimulatory molecule expression

[0470] The TSS, TSG, TIS, and TIG clones were tested for their ability to inhibit the expression of B-cell costimulatory molecules (CD80, CD86) at different concentrations (2, 4, 6, 8, and 10 μg / ml). As a result, the TSG clone was found to have the highest ability to inhibit the expression of B-cell costimulatory molecules (Fig. 24). Consequently, the TSG clone was selected as the lead antibody (hu3E-3) for the humanized antibody, and the TSS, TIS, and TIG clones were secured as back-up antibodies. The humanized TSG clone contains only two chicken-derived residues in the framework region, and the remaining regions are all substituted identically to the human germline sequence.

[0471]

[0472] Among the above eight clones, the CDR and variable region sequences of the TSG clone are summarized in the table below:

[0473] [TSG clone (hu3E-3 clone)] Region sequence L-CDR1SGGYSSYGIYYYG (SEQ ID NO: 1) L-CDR2NGNKRPS (SEQ ID NO: 4) L-CDR3GSGDSSSDSGI (SEQ ID NO: 7) H-CDR1GFTFSSYGMN (SEQ ID NO: 10) H-CDR2AISNDGSSTSYAPAVKG (SEQ ID NO: 13) H-CDR3ESTNGGWVADDIDA (SEQ ID NO: 16) VLELTQDPAVSVALGQTVRITCSGGYSSYGIYYYGWYQQKPGQAPV[T]VIYNGNKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCGSGDSSSDSGIFGGGTKLTVL (SEQ ID NO: 48) Linker GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93)VHEVQLVESGGGLVQPGGSLRL[S]CAASGFTFSSYGMNWVRQAPGKGLEWV[G]AISNDGSSTSYAPAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKESTNGGWVADDIDAWGQGTLVTVSS (SEQ ID NO: 53)

[0474] In the above table, the CDR sequences (L-CDR1, L-CDR2, L-CDR3, H-CDR1, H-CDR2, H-CDR3) included in the light chain variable region and heavy chain variable region are underlined. In addition, the 12th residue from the N'terminus of the L-FR2 region, the 21st residue from the N'terminus of the H-FR1 region, and the 14th residue from the N'terminus of the H-FR2 region are indicated with square brackets and bold underlines.

[0475]

[0476] 1.4.5. Measurement of binding affinity of anti-CD40L antibodies

[0477] The binding affinity of three anti-CD40L antibodies (1H-8 clone, TSG clone, and 3E-3 clone) to CD40L was measured. Antigen-antibody binding was measured using a Biacore T200 (GE Healthcare) at 25°C by surface plasmon resonance (SPR). Binding affinity measurement using Biacore is performed by injecting analyte onto the ligand-immobilized chip surface and going through the association, dissociation, and regeneration processes (see schematic diagram in Figure 25). Affinity measurement values ​​were calculated using the 1:1 binding model of BIAevaluation software version 1.0.

[0478] The binding strength was measured by immobilizing CD40L (rhCD40 Ligand, R&D system, 6420-CL / CF) protein on the CM5 chip surface. The rhCD40 Ligand was immobilized on the CM5 chip surface at a level of 100 RU under pH 5.5 conditions. HBS-EP (GE Healthcare, BR-10-0669) was used as the sample and system buffer. The binding strength was measured with three types of dual antibodies in the form of scFv-Ck-scFv [the structure of anti-CD40L scFv antibody (N'-VL-VH-C')-Ck-anti-cotinine antibody (N'-VL-VH-C'), see Example 1-1] at a flow rate of 30 μl / min with association / dissociation times of 4 min / 3 min, respectively. For each cycle, 10 mM Glycine-HCl (pH 2.0) was regenerated for 30 s at a flow rate of 30 μl / min.

[0479] Table 12 below shows the conditions for measuring the binding affinity of anti-CD40L antibodies.

[0480]

[0481] As the CD40L binding affinity measurement results using the multi-kinetics method showed that antibody regeneration was not stable, additional experiments were performed using the single kinetics method that did not perform the regeneration step, and the results are shown in Figures 26a and 26b, respectively.

[0482]

[0483] K according to single kinetics and multi kinetics methods D It is known that the values ​​do not differ, and in this example, the K of 1H8 clone, TSG clone and 3E-3 clone between the two methods D It was confirmed that there was no significant difference in the values.

[0484]

[0485]

[0486] Example 2. Anti-CD28 antibody

[0487] Example 2-1. Anti-CD28 antibody screening (lead antibody)

[0488] An antibody library in the form of scFv was prepared by immunizing chickens (Biopore, White leghorn chicken, 3) with human CD28 recombinant protein (R&D Systems, Minneapolis, MN, USA). The complexity of the three chicken antibody libraries prepared was 1.5 x 10 9 , 1.3 x 10 9 , 1.3 x 10 9 , 9.4 x 10 8 Biopanning was performed against human CD28 using a chicken antibody library. Subsequently, 49 clones that bind to human CD28 were selected through enzyme-linked immunosorbent assay, and their genetic information was obtained through base sequence analysis (Fig. 27).

[0489]

[0490] In order to produce 12 antibody clones that bind to human CD28 recombinant protein in the form of scFv-Ck-scFv-HIS-HA fusion proteins [anti-CD28 scFv antibody (N'-VL-linker-VH-C') - Ck (SEQ ID NO: 95) - anti-cotinine scFv antibody (N'-VL-linker-VH-C') - HIS-HA, see Example 1-1], cloning was performed into an animal cell expression vector, and after transforming human embryonic kidney (human embryonic kidney 293F, HEK293F) cells, antibodies were purified from the cell culture medium through affinity chromatography.

[0491] Transfection volume (mL)Quantificationμgmg / LFR10450470.942-75089517.94-650121924.44-145053210.64-8501149234-775 025056-15076315.26-8501773.546-2502074.146-35071814.36-5502204.46-1850114929.66-73504478.94

[0492] 2.1.1. Confirmation of binding to human CD28

[0493] The expressed and purified anti-CD28 antibody was confirmed to bind to Jurkat E6.1 (Human CD28+) cell line (ATCC, Manassas, VA, USA) by flow cytometry. As a positive control, an antibody that specifically binds to CD28 (FR104 clinical candidate from OSE Immunotherpies, J Immunol. 2016. 197(12):4593-4602) was cloned and purified in the same manner for comparison.

[0494]

[0495] As a result, it was confirmed that 12 kinds of expressed and purified anti-CD28 antibodies bound to the Jurkat E6.1 (Human CD28+) cell line (Fig. 28).

[0496]

[0497] 2.1.2. Inhibitory activity of cytokine secretion in Jurkat E6.1 cell line (in vitro)

[0498] For T cells to be activated, the T cell receptor (TCR) on the surface of the T cell must recognize the antigen presented on the surface of an antigen-presenting cell (APC). At this time, it is known that T cells are activated by receiving a signal (signal 1) transmitted through the TCR and a costimulatory signal (signal 2) transmitted when B7 molecules (B7.1 [CD80], B7.2 [CD86]) on the surface of the APC bind to CD28 on the surface of the T cell (Cancer Res. 2001 61(5): 1976-82).

[0499] Therefore, we evaluated whether the anti-CD28 antibody could inhibit the activation of human T cells by blocking CD28-B7 binding. When Jurkat E6.1 cells, a CD28-positive T cell line, were cultured with OKT3-Ck-HA antibody (US 5885573 A), a TCR stimulatory antibody, and Raji cells, a CD80 / CD86-positive B cell line, T cells were activated and secreted IL-2 (interleukin-2). We examined whether the IL-2 secretion ability of T cells was inhibited by treating the co-culture system with an anti-CD28 antibody.

[0500] Specifically, Jurkat E6.1 cell line, Raji cell line, OKT3 (10 nM) and anti-CD28 antibody (1 μM) were cultured together, and the supernatant of the culture was harvested after 48 hours to perform IL-2 ELISA. As a positive control group, the FR104 antibody was expressed in the form of FR104 scFv-Ck-Cot scFv [the structure of FR104 scFv antibody (N'-VL-VH-C')-Ck (SEQ ID NO: 95)-anti-cotinine antibody (N'-VL-VH-C'), see Example 1-1].

[0501]

[0502] As a result of confirming the inhibitory ability of 12 types of anti-CD28 antibodies to inhibit IL-2 secretion in Jurkat E6.1 cell lines, it was confirmed that J6-2 and J6-3 clones showed inhibitory ability similar to that of the positive control group (Fig. 29).

[0503]

[0504] To confirm whether the above experimental results could be reproduced in human primary T cells, additional experiments were performed. CD4-positive T cells and monocytes were isolated from healthy adult leukocytes obtained through leukapheresis using the MACS cell separation method. The isolated monocytes were differentiated into immature dendritic cells by treatment with GM-CSF (Granulocyte-macrophage colony-stimulating factor) and IL-4 (interleukin-4). These monocytes were then treated with LPS (lipopolysaccharide, 1 μg / ml) for 24 hours to mature and used as antigen-presenting cells for T cell stimulation. When CD4 T cells were cultured with the dendritic cells and an anti-CD3 antibody for TCR stimulation, T cell activation was induced. At this time, the anti-CD28 antibody was added to verify the inhibitory effect of T cell activation.

[0505] Specifically, CD4 T cells, dendritic cells, anti-CD3 antibody (2 μg / ml), and purified anti-CD28 antibody (10 μg / ml) were cultured together, and the supernatant was collected after 72 hours to perform IL-2 and IFN gamma (interferon gamma) ELISA.

[0506]

[0507] As a result, among the 12 anti-CD28 antibodies, the J6-3 clone showed higher IL-2 inhibitory activity than the positive control group (FR104) and showed IFN gamma secretion inhibitory activity similar to the positive control group (Figure 30).

[0508]

[0509] 2.1.3. Confirmation of competitive binding with CD80 / CD86 proteins

[0510] To reconfirm the binding specificity of the above J6-3 clone to T cell surface CD28, competitive binding ability was verified using recombinant CD80 and CD86 proteins.

[0511]

[0512] By treating Jurkat E6.1 cells with the J6-3 clone for 1 hour (1500 nM), all CD28 expressed on the Jurkat E6.1 cell surface was masked. After washing the Jurkat E6.1 cells, the cells were treated with CD80 and CD86 recombinant proteins (500 nM) to determine whether the J6-3 clone inhibited the binding of these recombinant proteins. The CD80 / CD86 proteins were analyzed for binding using a fluorescently labeled anti-Fc secondary antibody in the form of an Fc-fusion protein using a flow cytometer.

[0513]

[0514] As a result, it was confirmed that the binding affinity of CD80 / CD86 proteins was significantly reduced in cells treated with the J6-3 clone compared to cells not treated with the J6-3 clone. On the other hand, this decrease in binding affinity of CD80 / CD86 proteins was not observed in cells treated with the negative control antibody (J6-85 clone), thereby proving its specificity (Fig. 31).

[0515]

[0516] Thus, the J6-3 clone was confirmed to competitively bind to CD80 / CD86 protein on the cell surface CD28.

[0517]

[0518] The CDR and variable region sequences of the above J6-3 clone are summarized in the table below:

[0519] [J6-3 Clone] Region sequence L-CDR1SGGGSNNYG (SEQ ID NO: 65) L-CDR2YNDKRPS (SEQ ID NO: 66) L-CDR3GSRDSSHDGI (SEQ ID NO: 67) H-CDR1GFTFSTFNMF (SEQ ID NO: 68) H-CDR2QISSNDGSWTGYGAAVKG (SEQ ID NO: 70) H-CDR3AAGGYNVCGYGCGGDYIDA (SEQ ID NO: 71) VLMTQPSSVSANPGETVKITCSGGGSNNYGWYQQKSPGSAPVTVIYYNDKRPSGIPSRFSGSTSGSTGTLTITGVRAEDEAVYFCGSRDSSHDGIFGAGTTLTVL (SEQ ID NO: 87) Linker GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93)VHAVTLDESGGGLQTPGGALSLVCKASGFTFSTTFNMFWVRQAPGKGLEYVAQISSNDGSWTGYGAAVKGRATISRDNGQSTVRLQLNNLRAEDTATYYCAKAAGGYNVCGYGCGGDYIDAWGHGTEVIVSSTS (SEQ ID NO: 89)

[0520] In the above table, the CDR sequences (L-CDR1, L-CDR2, L-CDR3, H-CDR1, H-CDR2, H-CDR3) included in the light chain variable region and heavy chain variable region are underlined.

[0521]

[0522] Example 2-2. Anti-CD28 antibody screening (back-up antibody)

[0523] To secure additional backup antibodies other than the J6-3 clone from the anti-CD28 antibody library, clones that bind to CD28 were secured through screening. A number of additional antibody clones with binding affinity to CD28 were selected, genetic sequence analysis was completed, and the recombinant proteins were purified in the same form as the J6-3 clone. Anti-CD28 antibody (1000 nM) in the form of scFv-Ck-scFv [anti-CD28 scFv antibody (N'-VH-VL-C')-Ck-anti-cotinine antibody (N'-VH-VL-C'), see Example 1-1] was reacted with the CD28-positive Jurkat E6.1 cell line, and the binding to CD28 was confirmed by flow cytometry.

[0524]

[0525] As a result, it was confirmed that clones 4-25, 6-15, and 6-23 bound similarly to the positive control (FR104) (Fig. 32).

[0526]

[0527] Therefore, three backup antibody clones (clones 4-25, 6-15, and 6-23) that bind to the Jurkat E6.1 cell line similarly to the positive control group were secured.

[0528]

[0529] Example 2-3. Production of non-immunized and humanized antibodies (1)

[0530] To confirm the immunogenicity of the selected J6-3 clone through flow cytometry and interleukin-2 inhibitory activity experiment, immunogenicity analysis was performed using in silico antibody analysis by Abzena, UK (Fig. 33).

[0531] After confirming immunogenicity, the human germline sequence with the highest homology to the J6-3 clone selected in Example 2-1 was compared for de-immunization and simultaneous humanization (see schematic diagram in Fig. 34). A library was constructed using degenerate codons to change the human germline sequence in the immunogenic part of the complementary-determining region (CDR).

[0532] Bio-panning for human CD28 was performed using a random library containing the produced human germline, and various genetic information binding to human CD28 was obtained through base sequence analysis in enzyme-linked immunosorbent assay (Fig. 35).

[0533] Although the base sequence analysis results did not select a clone that perfectly matched the results of the existing immunogenicity analysis, it was confirmed that many complementarity determining regions were changed to the human germline compared to the existing 6-3 clone.

[0534] The clone with the most changes in position compared to the J6-3 clone was selected, and a library was constructed using the same method as described above, considering only the unchanged portions. The newly constructed library was then subjected to biopanning, enzyme-linked immunosorbent assay, and base sequence analysis to ultimately obtain clone number 95 (G12 clone) (Fig. 36).

[0535] The removal of immunogenicity of the selected clone G12 was reconfirmed, and as a result of analysis of the G12 clone, it was confirmed that there were two immunogenic sites (Fig. 37), and a library was created to change it to a human germline, and through bio-panning, enzyme immunoassay, and base sequence analysis, a clone with complete immunogenicity and humanization of the existing J6-3 clone was established (Fig. 38).

[0536] The clone that underwent the above-described non-immunization and humanization processes was designated the 2-G12 clone. The CDR and variable region sequences of the 2-G12 clone are summarized in the table below:

[0537] [2-G12 Clone] Region sequence L-CDR1SGGGSNNYG (SEQ ID NO: 65) L-CDR2YNDKRPS (SEQ ID NO: 66) L-CDR3GSRDSSHDGI (SEQ ID NO: 67) H-CDR1GFTFSSYAMH (SEQ ID NO: 69) H-CDR2QISSNDGSWTGYGAAVKG (SEQ ID NO: 70) H-CDR3AAGGYNVCGYGCGGDYIDA (SEQ ID NO: 71) VLLTQPSSVSANPGETVKITCSGGGSNNYGWYQQKPGSAPVTVIYYNDKRPSGIPSRFSGSTSGSTGTLTITGVRAEDEAVYFCGSRDSSHDGIFGGGTKLTVL (SEQ ID NO: 88) Linker GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93)VHPVKLVESGGGLVTPGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVGQISSNDGSWTGYGAAVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCAKAAGGYNVCGYGCGGDYIDAWGHGTQVTVSSTS (SEQ ID NO: 90)

[0538] In the above table, the CDR sequences (L-CDR1, L-CDR2, L-CDR3, H-CDR1, H-CDR2, H-CDR3) included in the light chain variable region and heavy chain variable region are underlined.

[0539]

[0540] 2.3.1. Binding ability to human CD28

[0541] A humanized antibody clone (2-G12) that showed binding ability to human CD28 recombinant protein in phage enzyme-linked immunosorbent assay was cloned into the corresponding mammalian cell expression vector for expression in the form of scFv-Ck-scFv [anti-CD28 scFv antibody (N'-VH-VL-C')-Ck-anti-cotinine antibody (N'-VH-VL-C')]. The antibody was overexpressed through human embryonic kidney 293F (HEK293F) cell transformation, and the recombinant antibody was purified from the cell culture using affinity chromatography.

[0542]

[0543] Expressed and purified anti-CD28 antibodies (J6-3 clone and humanized 2-G12 clone) were expressed on Jurkat E6.1 (hCD28 + ) binding to cell lines was confirmed through flow cytometry (Fig. 39).

[0544]

[0545] Additionally, the binding of the J6-3 clone and the humanized 2-G12 clone to human CD28 recombinant protein (hCD28) (R&D Systems, Minneapolis, MN, USA) was confirmed by enzyme-linked immunosorbent assay (Fig. 40).

[0546]

[0547] 2.3.2. Inhibitory ability of CD4 T cells to secrete cytokines

[0548] As a result of confirming the cytokine secretion inhibition ability of CD4 T cells of the humanized 2-G12 clone, it was confirmed that the 2-G12 clone had a superior IL-2 (interleukin-2) secretion inhibition ability than the positive control group (FR104) and exhibited an IFN gamma inhibition ability similar to that of the positive control group (FR104) (Figure 41).

[0549]

[0550] Example 2-4. Production of humanized antibodies (2)

[0551] To improve antibody stability, additional humanization was performed by replacing the chicken-derived amino acid sequence remaining in the framework region of the 2-G12 clone with a sequence identical to the human germline sequence. As a result, a Hu2G12 clone was obtained in which 13 of the 23 chicken-derived residues in the existing 2-G12 framework region were additionally replaced with the human germline sequence. The replaced residues were the light chain (V L ) A13V, N14S, E17Q, V19A, K20R, S60D, T76S, R79Q and heavy chain (V H ) are P1E, K3Q, T13Q, H105Q, Q108E.

[0552]

[0553] The CDR and variable region sequences of the above Hu2G12 clone are summarized in Table 16 below:

[0554] [Hu2G12 Clone] Region sequence L-CDR1SGGGSNNYG (SEQ ID NO: 65) L-CDR2YNDKRPS (SEQ ID NO: 66) L-CDR3GSRDSSHDGI (SEQ ID NO: 67) H-CDR1GFTFSSYAMH (SEQ ID NO: 69) H-CDR2QISSNDGSWTGYGAAVKG (SEQ ID NO: 70) H-CDR3AAGGYNVCGYGCGGDYIDA (SEQ ID NO: 71) VLLTQPSSVSVSPGQTARITCSGGGSNNYGWYQQKPGSAPVTVIYYNDKRPSGIPERFSGSTSGSTGTLTISGVQAEDEAVYFCGSRDSSHDGIFGGGTKLTVL (SEQ ID NO: 98) Linker GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93)VHEVQLVESGGGLVQPGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVGQISSNDGSWTGYGAAVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCAKAAGGYNVCGYGCGGDYIDAWGQGTLVTVSSTS (SEQ ID NO: 99)

[0555] In the above table, the CDR sequences (L-CDR1, L-CDR2, L-CDR3, H-CDR1, H-CDR2, H-CDR3) included in the light chain variable region and heavy chain variable region are underlined, and the 10 non-humanized residues are indicated in bold.

[0556]

[0557] Example 2-5. Production of humanized antibodies (3)

[0558] In order to further humanize the 10 residues that were not humanized in the Hu2G12 clone prepared in Example 2-4 above, the light chain (V) of the remaining 10 chicken residues L ) of S42Q and T46L and heavy chain (V H ) introduced single mutations into the human germline sequence at residues G49S, S76N, and K94R, respectively, resulting in a total of five clones and heavy chains (V H ) Fully humanized V with all three residues changed HA clone was manufactured.

[0559] The above clones were named Hu2G12-S42Q (S42Q mutation in VL), Hu2G12-T46L (T46L mutation in VL), Hu2G12-G49S (G49S mutation in VH), Hu2G12-S76N (S76N mutation in VH), Hu2G12-K94R (K94R mutation in VH), and Hu2G12-G49S / S76N / K94R (G49S, S76N, K94R mutations in VH), respectively.

[0560] As an example, the CDR and variable region sequences of the Hu2G12-S42Q and Hu2G12-S76N clones are summarized in Tables 17 and 18 below:

[0561] [Hu2G12-S42Q clone] Region sequence L-CDR1SGGGSNNYG (SEQ ID NO: 65) L-CDR2YNDKRPS (SEQ ID NO: 66) L-CDR3GSRDSSHDGI (SEQ ID NO: 67) H-CDR1GFTFSSYAMH (SEQ ID NO: 69) H-CDR2QISSNDGSWTGYGAAVKG (SEQ ID NO: 70) H-CDR3AAGGYNVCGYGCGGDYIDA (SEQ ID NO: 71) VLLTQPSSVSVSPGQTARITCSGGGSNNYGWYQQKPGQAPVTVIYYNDKRPSGIPERFSGSTSGSTGTLTISGVQAEDEAVYFCGSRDSSHDGIFGGGTKLTVL (SEQ ID NO: 100)LinkerGQSSRSSGGGGSSGGGGSVHEVQLVESGGGLVQPGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVGQISSNDGSWTGYGAAVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCAKAAGGYNVCGYGCGGDYIDAWGQGTLVTVSSTS (SEQ ID NO: 99)

[0562] [Hu2G12-S76N clone] Region sequence L-CDR1SGGGSNNYG (SEQ ID NO: 65) L-CDR2YNDKRPS (SEQ ID NO: 66) L-CDR3GSRDSSHDGI (SEQ ID NO: 67) H-CDR1GFTFSSYAMH (SEQ ID NO: 69) H-CDR2QISSNDGSWTGYGAAVKG (SEQ ID NO: 70) H-CDR3AAGGYNVCGYGCGGDYIDA (SEQ ID NO: 71) VLLTQPSSVSVSPGQTARITCSGGGSNNYGWYQQKPGSAPVTVIYYNDKRPSGIPERFSGSTSGSTGTLTISGVQAEDEAVYFCGSRDSSHDGIFGGGTKLTVL (SEQ ID NO: 98)LinkerGQSSRSSGGGGSSGGGGSVHEVQLVESGGGLVQPGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVGQISSNDGSWTGYGAAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKAAGGYNVCGYGCGGDYIDAWGQGTLVTVSSTS (SEQ ID NO: 101)

[0563]

[0564] Example 3. Anti-CD40L / anti-CD28 bispecific antibody

[0565] Example 3-1. Anti-CD40L / anti-CD28 bispecific antibody (1)

[0566] Anti-CD40L / anti-CD28 bispecific antibodies were prepared in which each anti-CD40L antibody and anti-CD28 antibody were conjugated in the form of a monovalent antibody.

[0567] To produce an exemplary anti-CD40L / anti-CD28 bispecific antibody of the above type, the humanized anti-CD40L scFv antibody TSG clone produced in Example 1-4 and the humanized anti-CD28 scFv antibody 2-G12 antibody produced in Example 2-3 were cloned into a bispecific antibody form containing a Ck linking domain and then expressed in a mammalian expression system (see schematic diagrams in FIGS. 42 and 67). Specifically, the antibody was overexpressed through human embryonic kidney 293F (HEK293F) cell transformation, and the recombinant antibody was successfully purified from the cell culture using affinity chromatography (FIG. 43).

[0568] Figure 43 above shows the SDS-PAGE results of anti-CD40L / anti-CD28 bispecific antibodies.

[0569]

[0570] The full sequences of anti-CD40L / anti-CD28 bispecific antibodies are shown in Tables 19 and 20 below. The bispecific antibody in Table 19 contains, from the N'-terminus, anti-CD40L antibody (TSG clone), Ck region (SEQ ID NO: 95), and anti-CD28 antibody (2-G12 clone), and the bispecific antibody in Table 20 contains, from the N'-terminus, anti-CD28 antibody (2-G12 clone), Ck region (SEQ ID NO: 95), and anti-CD40L antibody (TSG clone). The bispecific antibody in Table 19 below was named TSGx2-G12, and the bispecific antibody in Table 20 was named 2-G12xTSG.

[0571] [N'-(TSG scFv)-linker-Ck-linker-(2-G12 scFv)-C'; TSGx2-G12]Antibody site sequence TSGVLELTQDPAVSVALGQTVRITCSGGYSSYGIYYYGWYQQKPGQAPVTVIYNGNKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCGSGDSSSDSGIFGGGTKLTVL (SEQ ID NO: 48)Linker GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93) VHEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMNWVRQAPGKGLEWVGAISNDGSSTSYAPAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKESTNGGWVADDIDAWGQGTLVTVSS (SEQ ID NO: 53)Linker-Ck-linkerLinker GQAGQ [SfiI site] - GGGGSGGGGSGGGGS (SEQ ID NO: 94) - KL [HindIII site] CkRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSLPVTKSFNRGES (SEQ ID NO: 95) Linker LE [XhoI site] - GGGGSGGGGSGGGGS (SEQ ID NO: 94) - TG [Agel site] 2-G12VLLTQPSSVSANPGETVKITCSGGGSNNYGWYQQKPGSAPVTVIYYNDKRPSGIPSRFSGSTSGSTGTLTITGVRAEDEAVYFCGSRDSSHDGIFGGGTKLTVL (SEQ ID NO: 88) Linker GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93)VHPVKLVESGGGLVTPGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVGQISSNDGSWTGYGAAVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCAKAAGGYNVCGYGCGGDYIDAWGHGTQVTVSSTS (SEQ ID NO: 90) Full sequence [N'-(TSG scFv) - linker-Ck-linker - (2-G12scFv)-C']ELTQDPAVSVALGQTVRITCSGGYSSYGIYYYGWYQQKPGQAPVTVIYNGNKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCGSGDSSSDSGIFGGGTKLTVLGQSSRSSGGGGSSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMNWVRQAPGKGLEWVGAISNDGSSTSYAPAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKESTNGGWVADDIDAWGQGTLVTVSSGQAGQGGGGSGGGGSGGGGSKLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSLPVTKSFNRGESLEGGGGSGGGGSGGGGSTGLTQPSSVSANPGETVKITCSGGGSNNYGWYQQKPGSAPVTVIYYNDKRPSGIPSRFSGSTSGSTGTLTITGVRAEDEAVYFCGSRDSSHDGIFGGGTKLTVLGQSSRSSGGGGSSGGGGSPVKLVESGGGLVTPGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVGQISSNDGSWTGYGAAVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCAKAAGGYNVCGYGCGGDYIDAWGHGTQVTVSSTS (서열번호 96)

[0572] [N'-(2-G12 scFv)-linker-Ck-linker-(TSG scFv)-C'; 2-G12xTSG]Antibody site sequence 2-G12VLLTQPSSVSANPGETVKITCSGGGSNNYGWYQQKPGSAPVTVIYYNDKRPSGIPSRFSGSTSGSTGTLTITGVRAEDEAVYFCGSRDSSHDGIFGGGTKLTVL (SEQ ID NO: 88)Linker GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93)VHPVKLVESGGGLVTPGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVGQISSNDGSWTGYGAAVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCAKAAGGYNVCGYGCGGDYIDAWGHGT QVTVSSTS (SEQ ID NO: 90)Linker-Ck-LinkerLinker GQAGQ [SfiI site] - GGGGSGGGGSGGGGS (SEQ ID NO: 94) - KL [HindIII site] CkRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSLPVTKSFNRGES (SEQ ID NO: 95) Linker LE [XhoI site] - GGGGSGGGGSGGGGS (SEQ ID NO: 94) - TG [Agel site] TSGVLELTQDPAVSVALGQTVRITCSGGYSSYGIYYYGWYQQKPGQAPVTVIYNGNKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCGSGDSSSDSGIFGGGTKLTVL (SEQ ID NO: 48) Linker GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93)VHEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMNWVRQAPGKGLEWVGAISNDGSSTSYAPAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKESTNGGWVADDIDAWGQGTLVTVSS (SEQ ID NO: 53) Full sequence [N'-(2-G12 scFv) - linker-Ck-linker -(TSG scFv)-C']LTQPSSVSANPGETVKITCSGGGSNNYGWYQQKPGSAPVTVIYYNDKRPSGIPSRFSGSTSGSTGTLTITGVRAEDEAVYFCGSRDSSHDGIFGGGTKLTVLGQSSRSSGGGGSSGGGGSPVKLVESGGGLVTPGGSLRLSCSASGFTFSSYAMHWVRQAPGKGLEYVGQISSNDGSWTGYGAAVKGRFTISRDNSKSTLYLQMNSLRAEDTAVYYCAKAAGGYNVCGYGCGGDYIDAWGHGTQVTVSSTSGQAGQGGGGSGGGGSGGGGSKLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSLPVTKSFNRGESLEGGGGSGGGGSGGGGSTGELTQDPAVSVALGQTVRITCSGGYSSYGIYYYGWYQQKPGQAPVTVIYNGNKRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCGSGDSSSDSGIFGGGTKLTVLGQSSRSSGGGGSSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMNWVRQAPGKGLEWVGAISNDGSSTSYAPAVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKESTNGGWVADDIDAWGQGTLVTVSS (서열번호 97)

[0573] 실시예 3-2. 항-CD40L / 항-CD28 이중 특이 항체 (2)

[0574] 3.2.1. 항-CD40L / 항-CD28 이중 특이 항체의 제조

[0575] In the same manner as in Example 3-1, the humanized anti-CD40L scFv antibody TSG clone prepared in Example 1-4 and the additional humanized anti-CD28 scFv antibody Hu2G12 clone prepared in Example 2-4 were cloned into the mammalian cell expression pCEP4 vector (Invitrogen, USA) in the form of a bispecific antibody containing a Ck linking domain ([N'-(TSG scFv) - linker-Ck-linker - (Hu2G12 scFv)-C']; TSGxHu2G12) and transformed into Expi293F (Gibco, USA) cells. Thereafter, the recombinant antibody was purified from the culture medium using affinity chromatography, and the purified recombinant antibody was confirmed by performing SDS-PAGE (Fig. 44). The bispecific antibody prepared above was named TSGxHu2G12.

[0576]

[0577] 3.2.2. Confirmation of binding affinity to CD28

[0578] It was confirmed whether the additional humanized anti-CD28 antibody portion of the bispecific antibody prepared in Example 3-2 preserved the binding affinity for CD28 and the inhibitory ability of CD28-CD80 (CD28 ligand) interaction.

[0579] To this end, the anti-CD40L / anti-CD28 bispecific antibody (TSGx2-G12, Table 19) prepared in Example 3-1 and the anti-CD40L / anti-CD28 bispecific antibody (TSGxHu2G12) prepared in Example 3-2 were treated with recombinant human CD28 protein (R&D systems, USA), and the binding strength was confirmed by enzyme-linked immunosorbent assay (ELISA). Specifically, after the recombinant CD28 protein (bound to the human Fc region) was coated on a 96-well plate (Corning, USA), blocking was performed using 3% BSA / PBS (w / v). After reacting with TSGx2-G12 and TSGxHu2G12 for 2 hours, the plates were washed three times with 0.05% PBST (v / v), and treated with anti-hCk-HRP (Millipore, USA) for 1 hour. After the reaction was completed, washing was performed three more times, and color development was performed using ABTS (Thermo Scientific, USA). The absorbance was measured at 405 nm using a microplate reader (Thermo Scientific, USA), and the results are shown in Figure 45.

[0580]

[0581] As can be confirmed in the above Figure 45, TSGxHu2G12 showed CD28 binding affinity equivalent to that of TSGx2-G12 and CD28.

[0582]

[0583] 3.2.3. Confirmation of binding affinity to cell surface CD28

[0584] The above TSGxHu2G12 clone was reacted with the CD28-positive Jurkat E6.1 cell line, and the binding ability to CD28 expressed on the cell surface was confirmed through flow cytometry. Specifically, the Jurkat E6.1 cell line was reacted with the 2G-12 and Hu2G12 clones for 1 hour, and then washed three times using 1% BSA / PBS (w / v) with 0.02% NaN3 (v / v), and treated with anti-hCk-APC (AbCam, UK) and reacted for 1 hour. After completion of the reaction, three additional washes were performed, and fluorescence was detected using a flow cytometer (Becton Dickinson, USA), and the results are shown in Figure 46.

[0585]

[0586] As shown in Figure 46, it was confirmed that the bispecific antibody (TSGxHu2G12) containing the Hu2G12 clone had a similar binding affinity to the bispecific antibody (TSGx2-G12) containing the 2-G12 clone. (Figure 46)

[0587]

[0588] 3.2.4. Confirmation of CD28-CD80 interaction inhibition ability

[0589] To evaluate the CD28-CD80 interaction inhibition ability of the TSGxHu2G12 clone, 2G-12 and Hu2G12 clones (100 nM or 1000 nM) were bound to CD28-positive Jurkat E6.1 cells for 1 hour, and then washed three times with 1% BSA / PBS (w / v) with 0.02% NaN3 (v / v), and 1 mg of recombinant CD80 protein (Sino biological, China) was reacted for 1 hour. After the reaction, 3 washes were performed, and after reacting with anti-hFc-FITC (Invitrogen, USA) that can detect the recombinant CD80 protein, 3 washes were performed. After that, fluorescence was measured using a flow cytometer (Beckton Dickinson, USA) to confirm whether the TSGxHu2G12 clone could inhibit the CD28 binding of the recombinant CD80 protein, and the results are shown in Fig. 48. Figure 47 shows a schematic diagram of the above experiment.

[0590]

[0591] As a result, it was confirmed that the bispecific antibody (TSGxHu2G12) containing the Hu2G12 clone inhibited the binding of recombinant CD80 protein at an antibody concentration of 1000 nM to a similar degree as the bispecific antibody (TSGx2-G12) containing the 2-G12 clone. (Figure 48)

[0592]

[0593] Example 3-3 Anti-CD40L / anti-CD28 bispecific antibody (3)

[0594] 3.3.1. Preparation of anti-CD40L / anti-CD28 bispecific antibodies

[0595] In the same manner as in Example 3-1, the humanized anti-CD40L scFv antibody TSG clone prepared in Example 1-4 and the additional humanized anti-CD28 scFv antibodies Hu2G12-S42Q, Hu2G12-T46L, Hu2G12-G49S, Hu2G12-S76N, Hu2G12-K94R, or Hu2G12-G49S / S76N / K94R clones prepared in Example 2-5 were cloned into the mammalian cell expression pCEP4 vector (Invitrogen, USA) in the form of a bispecific antibody containing a Ck linking domain, and Expi293F (Gibco, USA) cells were transformed. Thereafter, the recombinant antibody was purified from the culture medium using affinity chromatography, and the purified recombinant antibody was confirmed by performing SDS-PAGE. The bispecific antibodies prepared above were named TSGxHu2G12-S42Q, TSGxHu2G12-T46L, TSGxHu2G12-G49S, TSGxHu2G12-S76N, TSGxHu2G12-K94R, and TSGxHu2G12-G49S / S76N / K94R, respectively.

[0596]

[0597] 3.3.2. Confirmation of binding affinity to CD28

[0598] It was confirmed whether the additional humanized anti-CD28 antibody portion of the bispecific antibody prepared in Example 3-3 preserved the binding affinity for CD28 and the inhibitory ability of CD28-CD80 (CD28 ligand) interaction.

[0599] To this end, the anti-CD40L / anti-CD28 bispecific antibody (TSGx2-G12, Table 16) prepared in Example 3-1 and the anti-CD40L / anti-CD28 bispecific antibody (TSGxHu2G12-S42Q, TSGxHu2G12-T46L, TSGxHu2G12-G49S, TSGxHu2G12-S76N, TSGxHu2G12-K94R, TSGxHu2G12-G49S / S76N / K94R) prepared in Example 3-3 were treated with recombinant human CD28 protein (R&D systems, USA), and the binding strength was confirmed by enzyme-linked immunosorbent assay (ELISA) using the same method as in Example 3.2.2, and the results are shown in Fig. 49.

[0600]

[0601] As can be seen in the above Figure 49, among the six anti-CD40L / anti-CD28 bispecific antibodies manufactured by performing an additional humanization process in Example 3-3, the light chain (V L ) and a clone introducing the S42Q mutation into the heavy chain (V H ) showed binding affinity to CD28 equivalent to that of the anti-CD40L / anti-CD28 bispecific antibody (TSGx2-G12, Table 16) prepared in Example 3-1.

[0602]

[0603] 3.3.3. Confirmation of binding affinity to cell surface CD28

[0604] In Example 3.3.2, the TSGxHu2G12-S42Q and TSGxHu2G12-S76N clones, which showed CD28 binding affinity equivalent to that of the TSGx2-G12 clone, were reacted with the CD28-positive Jurkat E6.1 cell line, and the binding ability to CD28 expressed on the cell surface was confirmed through flow cytometry. Specifically, the Jurkat E6.1 cell line was reacted with the TSGx2-G12, TSGxHu2G12-S42Q, and TSGxHu2G12-S76N clones for 1 hour, and then washed 3 times using 1% BSA / PBS (w / v) with 0.02% NaN3 (v / v), and anti-hCk-APC (AbCam, UK) was treated and reacted for 1 hour. After the reaction was completed, three additional washes were performed, and fluorescence was detected using a flow cytometer (Becton Dickinson, USA), and the results are shown in Figure 50.

[0605]

[0606] As can be confirmed in the above Figure 50, the TSGxHu2G12-S42Q and TSGxHu2G12-S76N clones showed a slightly reduced binding affinity to cell surface CD28 compared to the TSGx2-G12 clone, but showed a similar level of binding affinity.

[0607]

[0608] 3.3.4. Confirmation of CD28-CD80 interaction inhibition ability

[0609] To evaluate the CD28-CD80 interaction inhibition ability of the above anti-CD40L / anti-CD28 bispecific antibodies, TSGx2-G12, TSGxHu2G12-S42Q, and TSGxHu2G12-S76N clones (100 nM, 250 nM, or 1000 nM) were bound to CD28-positive Jurkat E6.1 cells for 1 hour, followed by three washes with 1% BSA / PBS (w / v) with 0.02% NaN3 (v / v), and 1 mg of recombinant CD80 protein (Sino biological, China) was reacted for 1 hour. After the reaction, three washes were performed, and anti-hFc-Alexa Flour 594 (Jackson laboratory, USA), which can detect recombinant CD80 protein, was reacted, and three washes were performed. Afterwards, fluorescence was measured using a flow cytometer (Beckton Dickinson, USA), and the results are shown in Figure 52. Figure 51 shows a schematic diagram of the experiment.

[0610]

[0611] As can be confirmed in the above Figure 52, the TSGxHu2G12-S42Q and TSGxHu2G12-S76N clones exhibited recombinant CD80 protein binding inhibition ability equivalent to that of the TSGx2-G12 clone.

[0612]

[0613] Example 3-4. In vitro activity of anti-CD40L / anti-CD28 bispecific antibodies (T cell suppression ability)

[0614] For T cells to be activated, the T cell receptor (TCR) on the surface of the T cell must recognize the antigen presented on the surface of an antigen-presenting cell (APC). It is known that T cells are activated when they receive a signal (Signal 1) transmitted through the TCR, as well as a costimulatory signal (Signal 2) transmitted when B7 molecules (B7.1 [CD80], B7.2 [CD86]) on the surface of the APC bind to CD28 on the surface of the T cell.

[0615] Activated T cells induce the expression of CD40L, and when CD40L of CD4 T cells binds to CD40 on the surface of APC, CD40 transmits an activation signal to antigen-presenting cells, resulting in increased expression of MHC molecules and costimulatory molecules (CD80, CD86, 41BBL, etc.) on the surface of APC, and increased expression of T cell-stimulating cytokines such as IL-12. It is known that activated APCs in this way increase the activity of T cells through a positive feedback mechanism (schematic diagram in Figure 53).

[0616] Therefore, it was evaluated whether the above anti-CD40L / anti-CD28 bispecific antibody could simultaneously bind to CD40L and CD28 of CD4 T cells, block CD40L-CD40 and CD28-B7 binding, and consequently inhibit CD4 T cell activation.

[0617]

[0618] CD4-positive T cells and monocytes were isolated from healthy adult leukocytes obtained through leukapheresis using the MACS cell separation method (CD14 microbead, 130-050-201, Miltenyi Biotech). Monocytes were differentiated into dendritic cells by treatment with GM-CSF (20 ng / ml, JW Creagene, rhGM-CSF) and IL-4 (20 ng / ml, JW Creagene, rhIL-4) for 5 days.

[0619] CD4-positive T cells were isolated from the leukocyte fraction of the same donor by the MACS cell separation method (CD4 microbead, 130-097-048, Miltenyi Biotech), added to differentiated dendritic cells, and co-cultured with anti-CD3 antibody (clone OKT3, 1ug / ml, 50-561-956, Bio X cell) for TCR stimulation. To maintain sufficient distance between T cells in the culture space, B cells isolated from the leukocyte fraction of the same donor by the MACS cell separation method (CD19 microbead, 130-050-301, Miltenyi Biotech) were irradiated to prevent division, and then added as bystander cells for culture. The T cell suppressive efficacy of the bispecific antibody was evaluated by adding the bispecific antibody to the above co-culture conditions.

[0620] A schematic diagram of the above experimental process is shown in Figure 54.

[0621]

[0622] The results of the above experiment are shown in Fig. 55. At this time, the CD28-only inhibitory antibody (aCot-Ck-aCD28; aCot-Ck-2-G12) tested together also showed an IFNr inhibitory effect similar to that of the dual antibody (TSGx2-G12), but the IFNr inhibitory effect of the CD40L-only inhibitory antibody (aCD40L-Ck-aCot; TSG-Ck-aCot) was not observed. Therefore, the T cell activation inhibitory effect of the bispecific antibody under these experimental conditions is considered to be mainly due to the inhibitory effect on CD28. This is interpreted as a result of the fact that the CD40L inhibitory effect was not observed under the 48-hour culture condition for observing the initial activation of T cells, since CD40L is expressed only in activated T cells.

[0623]

[0624] Example 3-5. In vitro activity of anti-CD40L / anti-CD28 bispecific antibodies (induction of T cell immune tolerance)

[0625] Immune tolerance is a mechanism by which the human immune system prevents autoimmune diseases. It refers to a phenomenon in which, when self-antigen-specific T cells recognize self-antigens presented by antigen-presenting cells and receive a TCR signal (signal 1), they are not activated even if they receive self-antigen stimulation again later if they do not receive co-stimulation (signal 2) from the antigen-presenting cells (see schematic diagram in Figure 56).

[0626] In this example, it was confirmed that the anti-CD40L antibody (TSG clone), anti-CD28 antibody (2-G12 clone), and anti-CD40L / anti-CD28 bispecific antibody (TSGx2-G12 clone) simultaneously blocked CD40L and CD28 co-stimulation at the T cell activation stage, and then promoted immune tolerance in which these T cells were not activated even when they were re-stimulated.

[0627] Similar to the experiment of the initial stage of T cell activation mentioned above, human CD4 T cells, dendritic cells, and irradiated B cells were co-cultured with anti-CD3 antibody to induce CD4 T cell activation, and then co-stimulation was blocked by adding a bispecific antibody (to induce immune tolerance). After 7 days, these CD4 T cells were stimulated again with new dendritic cells and anti-CD3 antibody, and the unresponsiveness of the T cells was evaluated. The unresponsiveness of the T cells was evaluated by measuring IFNr secretion in the culture supernatant 48 hours after antigen restimulation using the ELISA method.

[0628] A schematic diagram of the above experimental process is shown in Figure 57.

[0629]

[0630] The results of the above experiment are shown in Fig. 58.

[0631] In the case of CD40L monospecific antibodies or CD28 monospecific antibodies, the amount of IFNr secretion was slightly reduced compared to the negative control antibody, confirming that the monospecific antibodies also have an immune tolerance-inducing effect. In the group treated with anti-CD40L / anti-CD28 bispecific antibodies, the amount of IFNr was significantly reduced compared to the negative control group, confirming that CD4 T cells treated with the bispecific antibodies did not respond even upon antigen restimulation (Figure 58). Therefore, it was confirmed that the bispecific antibodies possess a remarkable immune tolerance-inducing promoting effect.

[0632]

[0633] Additionally, the efficacy of various forms of anti-CD40L / anti-CD28 bispecific antibodies (anti-CD40L-Ck-CD28 bispecific antibodies and anti-CD28-Ck-CD40L bispecific antibodies) was compared. Two forms of anti-CD40L / anti-CD28 bispecific antibodies (anti-CD40L antibody - anti-CD28 antibody and anti-CD28 antibody - anti-CD40L antibody) were prepared, and the inhibition of IFNr production 48 hours later was measured by ELISA. As a result, it was confirmed that both antibodies effectively inhibited T cell activation (Figure 59), confirming that excellent T cell suppression ability exists regardless of the order of anti-CD40L antibody and anti-CD28 antibody.

[0634]

[0635] Example 3-6. Confirmation of cis-interaction of anti-CD40L / anti-CD28 bispecific antibodies.

[0636] The anti-CD40L / anti-CD28 bispecific antibody provided in the present application can inhibit the functions of CD40L and CD28 expressed on T cells by independently binding to each of the two molecules, and can simultaneously inhibit both molecules expressed on a single T cell by simultaneously binding to both CD40L and CD28 molecules expressed on the same T cell (cis-interaction). This simultaneous inhibition method (linked inhibition) can exhibit a superior effect compared to the separate inhibition method. A schematic diagram of the simultaneous inhibition method and the separate inhibition method is shown in Figure 60.

[0637] In this example, a Fluorescence resonance energy transfer (FRET) experiment was performed to confirm that the anti-CD40L / anti-CD28 bispecific antibody acts in a linked inhibition manner through cis-interaction on T cells.

[0638]

[0639] CD28 recombinant receptor [N'-Extracellular domain-Transmembrane domain-Cytoplasmic domain-linker-mNeongreen-C'] (Addgene, [#113400] pEF6a-CD28-PafA) and CD40L recombinant receptor [N'-mScarlet-linker-Cytoplasmic domain-Transmembrane domain-Extracellular domain-C'] (Addgene, [#52337] CD154-His-bio) conjugated with fluorescent proteins were cloned into the pRK5 expression vector, and then 0.5 mg and 1 mg of DNA, respectively, were simultaneously transfected into human embryonic kidney 293A (HEK293A) cells cultured for 24 hours using Lipofectamine 2000 (Invitrogen, USA). After 24 hours, PMA (Phorbol myristate acetate) was treated and cultured for an additional 12 hours to induce cell activation, and activated HEK293A cells were treated with 75 nM of anti-CD40L-Ck-CD28 bispecific antibody in the form of scFv-Ck-scFv and anti-CD40L (anti-CD40L scFv-Ck-cotinine scFv) or anti-CD28 (anti-cotinine scFv-Ck-CD28 scFv) antibodies or a mixture thereof (anti-CD40L antibody + anti-CD28 antibody), and two control antibodies of the same form, respectively, and observed for 10 minutes.

[0640] Afterwards, the fluorescence of CD40L-mScarlet was photobleached by irradiating it with an ND4 filter for 1 minute through a neutral density (ND) filter adjustment that can control the light intensity using an mCherry filter (Excitation 562 / 40, dichroic mirror 593, Emission 641 / 75). The change in mCherry fluorescence after photobleaching was approximately -80% on average, and the degree of fluorescence change of mNeonGreen (FITC intensity) in the cell membrane region was measured to calculate the degree of Fφrster resonance energy transfer (FRET) [(FITC intensity after photobleaching-FITC intensity before photobleaching) / FITC intensity after photobleaching].

[0641]

[0642] The results of the above experiment are shown in Figs. 61 and 62.

[0643] As a result of the experiment, it was confirmed that CD40L and CD28 were co-localized at the same location only in the group treated with anti-CD40L-Ck-CD28 bispecific antibody.

[0644]

[0645] In addition, the results of calculating the FRET efficacy by measuring the degree of fluorescence change of CD28-mNeonGreen in the cell membrane region after photobleaching are shown in Figures 63 and 64, and it was confirmed that only in the group treated with the anti-CD40L-Ck-CD28 bispecific antibody, the CD28-mNeonGreen fluorescence in the cell membrane region significantly changed, and the FRET efficacy value had statistical significance compared to other groups, which means that the anti-CD40L-Ck-CD28 bispecific antibody expressed on the cell surface binds to CD40L and CD28 expressed on the same cell surface through cis-interaction.

[0646] Therefore, it was suggested that the anti-CD40L-Ck-CD28 bispecific antibody may act in a simultaneous manner in addition to individual inhibition of CD40L and CD28 through cis-interaction.

[0647]

[0648] Example 3-7. In vivo activity of anti-CD40L / anti-CD28 bispecific antibodies

[0649] In vivo models of human T cell-mediated autoimmune diseases are difficult to establish in experimental animals such as mice. However, a mouse model similar to autoimmune diseases exists: the xenogeneic GVHD (graft versus host disease) mouse model, in which human T cells induce an inflammatory immune disease. This mouse model, when infused with human T cells into immunodeficient mice, induces a T cell-mediated inflammatory disease by recognizing and attacking xenoantigens of the mouse. It shares a similar mechanism to autoimmune diseases in that inflammation is induced by T cell overactivation. Therefore, assessing the degree of inflammatory disease induction in mice can assess the degree of human T cell overactivation. Furthermore, suppression of human T cell activity by T cell inhibitors and subsequent alleviation of inflammatory disease can be observed, providing a model that mimics the suppressive effects of autoimmune diseases. Therefore, it can be used as an appropriate model for evaluating the in vivo functions of human anti-CD40L antibodies and human CD28 antibodies.

[0650] In addition, this model can be used as a model to simulate allogeneic GVHD that can occur in patients with hematopoietic cancer after hematopoietic stem cell transplantation due to transplanted donor T cells, and thus can be used as a model to evaluate the efficacy of antibodies as a treatment for GVHD caused by T cell overactivation in addition to autoimmune diseases.

[0651] Therefore, in this example, we established a xenogeneic GVHD mouse model using human T cells and verified the anti-inflammatory disease inhibitory effects of anti-CD40L antibodies and anti-CD28 antibodies. Peripheral blood mononuclear cells (PBMC, 1x10) isolated from the peripheral blood of healthy adults were injected into NSG mice (immunodeficient mice) (NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl / SzJ), Jackson Laboratory, #005557). 7 After intravenous injection of the mouse, the disease severity was scored based on weight loss and clinical symptoms to monitor the progression of the disease.

[0652] The experimental groups were divided into the following groups: no antibody treatment group (PBMC), anti-CD40L antibody (TSG clone) treatment group (PBMC+aCD40L), anti-CD28 antibody (2-G12 clone) treatment group (PBMC+aCD28), anti-CD40L and anti-CD28 antibody combination treatment group (PBMC+aCD40L+aCD28), and anti-CD40L / anti-CD28 bispecific antibody treatment group (PBMC+aCD40L-aCD28, PBMC+aCD28-aCD40L). The experiment was conducted by intraperitoneally injecting 400 μg of antibody into the mice three times a week for a total of nine times.

[0653] The body weight results were data-based on the body weight of the mouse before it died.

[0654]

[0655] The experimental results are shown in Figs. 65 and 66.

[0656] In the group that was not treated with antibodies (negative control group, PMBC), the disease was confirmed to have developed after 30 days by weight loss.

[0657] The groups treated with either anti-CD40L or anti-CD28 antibodies alone showed similar body weight loss to the negative control group, disease progression similar to the negative control group in disease severity assessments, and all mice died within a similar period of time as the negative control group. This indicates that under the conditions of this GVHD model, disease progression cannot be inhibited by inhibition of a single co-stimulatory molecule alone. However, this does not mean that the two monoclonal antibodies have no efficacy in vivo, given their ability to suppress T cell and antigen-presenting cell activation in vitro.

[0658] The group treated with a combination of anti-CD40L and anti-CD28 antibodies showed slower weight loss compared to the control group, and the disease severity assessment showed slower disease progression compared to the control group. In addition, the survival time of the mice was confirmed to be longer compared to the group treated with each antibody alone, indicating that combined therapy of the two antibodies can further suppress disease progression. This result demonstrates the partial efficacy of the single antibodies and proves that combined therapy of these two antibodies can have a synergistic effect. However, the current antibody administration regimen could not completely suppress disease progression, resulting in weight loss and eventual death of the mice.

[0659] In contrast, the group treated with the anti-CD40L / anti-CD28 bispecific antibody showed no weight loss during the experimental period, and no disease development was confirmed in the disease severity assessment. In addition, all mice survived during the experimental period, confirming that disease progression was completely suppressed only in the group treated with the bispecific antibody. This result explains the superiority of the bispecific antibody form, which simultaneously exists two antibody sites within a single molecule, compared to the combined treatment of two single antibodies, and explains the conceptual originality of the simultaneous inhibitory effect on CD40L and CD28 (linked inhibition). However, this result does not negate the partial efficacy of each single antibody or the single efficacy when each single antibody is produced in a form other than the scFv form.

[0660]

[0661] Example 4. Anti-CD40L / anti-CD28 bispecific antibody for mice

[0662] Example 4-1. Preparation of anti-CD40L / anti-CD28 bispecific antibodies for mice

[0663] As previously explained, it is theoretically difficult to implement an animal model of autoimmune disease using overactivation of human T cells in laboratory animals. In this example, to further support the anti-CD40L / anti-CD28 bispecific antibody provided by the present application and its autoimmune disease therapeutic effect, an anti-CD40L / anti-CD28 bispecific antibody (surrogate antibody) against mouse CD28 and mouse CD40L was treated in an autoimmune disease mouse model, and the autoimmune disease therapeutic effect was confirmed.

[0664] The present application newly proposes an anti-CD40L / anti-CD28 bispecific antibody in the form of a monovalent antibody in which each anti-CD40L antibody and anti-CD28 antibody are linked, and its use in the treatment of autoimmune diseases. Therefore, the preparation examples of the anti-CD40L / anti-CD28 bispecific antibody for mice in which each antibody is linked in the form of a monovalent antibody and its excellent autoimmune disease treatment effect should be interpreted as supporting the anti-CD40L / anti-CD28 bispecific antibody provided by the present application and its autoimmune disease treatment effect.

[0665]

[0666] 4.1.1. Anti-mouse CD28 antibody

[0667] The anti-mouse CD28 antibody used the scFv sequence of the PV-1 clone (Plos One 2017; 12(3):e0171822, Novel CD28 antagonist mPEG PV1-Fab' mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production). The CDR and variable region sequences of the PV-1 clone (scFv) are shown in Table 21 below.

[0668] [PV1 (anti-mCD28)] Region Sequence LCDR1RSSQSLYYSGIKKNLLA (SEQ ID NO: 102) LCDR2FTSTRLP (SEQ ID NO: 103) LCDR3QQGISTPLT (SEQ ID NO: 104) HCDR1DGYMN (SEQ ID NO: 105) HCDR2RIDPDSGNTRYNQKFQG (SEQ ID NO: 106) HCDR3DGTFYGTYGYWYFDF (SEQ ID NO: 107) VLDIVMTQSPYSLAVSAGEKVTMSCRSSQSLYYSGIKKNLLAWYQQKPGQSPKLLIYFTSTRLPGVPDRFTGSGSGTDYTLTITSVQAEDMGHYFCQQGISTPLTFGDGTKLEIR (SEQ ID NO: 108) Linker GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93)VHQVQLKQSGAELVKPGASVKISCKTSGYTFTDGYMNWVEQKPGQGLEWIGRIDPDSGNTRYNQKFQGKATLTRDKSSSTVYMDLRSLTSEDSAVYYCARDGTFYGTYGYWYFDFWGQGTQVTVSS (SEQ ID NO: 109)

[0669] 4.1.2. Anti-mouse CD40L antibody

[0670] Anti-mouse CD40L antibodies were newly prepared and used from chickens immunized with mouse CD40L protein.

[0671] A scFv antibody library was produced by immunizing chickens four times with mouse CD40L recombinant protein (Sino Biological, China) using a previously reported method. The complexity of the three chicken antibody libraries produced was 5.0x10 9 , 5.8x10 9 , 6.3x10 9 Im. Bio-panning was performed on mouse CD40L (R&D systems, USA) using a chicken antibody library, and 16 clones that bind to mouse CD40L were selected using phage-enzyme-linked immunosorbent assay, and their genetic information was obtained through base sequence analysis.

[0672] Among 16 antibody clones that bind to mouse CD40L recombinant protein, 8 clones with different HCDR3s were cloned into the pCEP4 (Invitrogen, USA) vector for animal cell expression to produce scFv-hFc fusion protein [anti-mouse CD40L scFv (N'-VL-linker-VH-C')-human Fc], and after transfection into Expi293F (Gibco, USA) cells, the antibodies were purified from the cell culture medium by affinity chromatography, and the purified recombinant antibodies were confirmed by performing SDS-PAGE.

[0673] The binding of the eight anti-mouse CD40L antibodies expressed above to the L (mCD154+) cell line (L4.5 cell line, DSMZ, Cat No. ACC 772) expressing mouse CD40L was confirmed by flow cytometry. Specifically, the anti-mouse CD40L antibodies were bound to the L (mCD154+) cell line at concentrations of 10, 100, and 1000 nM, and washed three times with 1% BSA / PBS (w / v) with 0.02% NaN3 (v / v). Then, anti-hFc-FITC (Invitrogen, USA) was diluted 1:100 and bound, washed three times, and fluorescence was detected using a flow cytometer (BD bioscience, USA). The results were expressed by comparing the mean fluorescence intensity (MFI) values, and it was confirmed that the 1-1-H, 1-12C, 1-12-H, 2-12-C, and 3-11-C clones effectively bound to mouse CD40L expressed on the cell surface in a concentration-dependent manner (Fig. 68).

[0674]

[0675] Based on the above results, the 2-12-C clone with the best binding affinity to mouse CD40L was selected. The CDR and variable region sequences of the 2-12-C clone are shown in Table 22 below.

[0676] [2-12-C (anti-mCD40L)] Region Sequence LCDR1SGGYSDYYG (SEQ ID NO: 110) LCDR2YNDKRPS (SEQ ID NO: 111) LCDR3GGYDGSTDAGI (SEQ ID NO: 112) HCDR1GFTFNNNGMA (SEQ ID NO: 113) HCDR2GISSGSYTYYGTAVKG (SEQ ID NO: 114) HCDR3DGSDYNWNSGADSIDA (SEQ ID NO: 115) VLLTQPSSVSANPGGTVEITCSGGYSDYYGWYQQKAPGSAPVTVIYYNDKRPSNIPSRFSGSTSGSTGTLTITGVQAEDEAIYYCGGYDGSTDAGIFGAGTTLTVL (SEQ ID NO: 116) LinkerGQSSRSSSGGGSSGGGGS (SEQ ID NO: 118)VHAVTLDESEGGLQTPGGALSLVCKASGFTFNNNGMAWVRQAPGKGLEFVAGISSGSYTYYGTAVKGRATISRDNGQSTVRLQLNNLRAEDTATYFCAKDGSDYNWNSGADSIDAWGHGTEVIVSS (SEQ ID NO: 117)

[0677] 4.1.3. Anti-CD40L / anti-CD28 bispecific antibody for mice

[0678] The PV1 antibody, an anti-mouse CD28 scFv antibody, and the 2-12-C clone, an anti-mouse CD40L scFv antibody discovered above, were cloned into a bispecific antibody form containing a human Ck linking domain [anti-mouse CD28 scFv antibody (N'-VL-VH-C')-Ck-anti-mouse CD40L scFv antibody (N'-VL-VH-C')], and then cloned into a mammalian cell expression pCEP4 (Invitrogen, USA) vector. Expi293F (Gibco, USA) cells were transformed, and the recombinant antibody was purified from the culture medium using affinity chromatography. The purified recombinant antibody was confirmed by performing SDS-PAGE.

[0679]

[0680] The above-mentioned anti-CD40L / anti-CD28 bispecific antibody for mice was named PV1x2-12-C clone, and each sequence is shown in Table 23 below.

[0681] [PV1 (anti-mCD28) x 2-12-C (anti-mCD40L)] Antibody region sequence PV1 VLDIVMTQSPYSLAVSAGEKVTMSCRSSQSLYYSGIKKNLLAWYQQKPGQSPKLLIYFTSTRLPGVPDRFTGSGSGTDYTLTITSVQAEDMGHYFCQQGISTPLTFGDGTKLEIR (SEQ ID NO: 108) Linker GQSSRSSGGGGSSGGGGS (SEQ ID NO: 93) VHQVQLKQSGAELVKPGASVKISCKTSGYTFTDGYMNWVEQKPGQGLEWIGRIDPDSGNTRYNQKFQGKATLTRDKSSSTVYMDLRSLTSEDSAVYYCARDGTFYGTYGYWYFDFWGQGTQVTVSS (SEQ ID NO: 109) Linker-Ck-LinkerLinkerGQAGQ [SfiI site] - GGGGSGGGGSGGGGS (SEQ ID NO: 94) - KL [HindIII site]CkRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSLPVTKSFNRGES (SEQ ID NO: 95) LinkerLE [XhoI site] - GGGGSGGGGSGGGGS (SEQ ID NO: 94) - TG [Agel site]2-12-CVLLTQPSSVSANPGGTVEITCSGGYSDYYGWYQQKAPGSAPVTVIYYNDKRPSNIPSRFSGSTSGSTGTLTITGVQAEDEAIYYCGGYDGSTDAGIFGAGTTLTVL (SEQ ID NO: 116) Linker GQSSRSSSGGGSSGGGGS (SEQ ID NO: 118) VHAVTLDESEGGLQTPGGALSLVCKAGFTFNNNGMAWVRQAPGKGLEFVAGISSGSYTYYGTAVKGRATISRDNGQSTVRLQLNNLRAEDTATYFCAKDGSDYNWNSGADSIDAWGHGTEVIVSS (SEQ ID NO: 117) Full sequence [N'-(PV1 scFv) - linker-Ck-linker -(2-12-C scFv)-C']DIVMTQSPYSLAVSAGEKVTMSCRSSQSLYYSGIKKNLLAWYQQKPGQSPKLLIYFTSTRLPGVPDRFTGSGSGTDYTLTITSVQAEDMGHYFCQQGISTPLTFGDGTKLEIRGQSSRSSGGGGSSGGGGSQVQLKQSGAELVKPGASVKISCKTSGYTFTDGYMNWVEQKPGQGLEWIGRIDPDSGNTRYNQKFQGKATLTRDKSSSTVYMDLRSLTSEDSAVYYCARDGTFYGTYGYWYFDFWGQGTQVTVSSGQAGQGGGGSGGGGSGGGGSKLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSLPVTKSFNRGESLEGGGGSGGGGSGGGGSTGLTQPSSVSANPGGTVEITCSGGYSDYYGWYQQKAPGSAPVTVIYYNDKRPSNIPSRFSGSTSGSTGTLTITGVQAEDEAIYYCGGYDGSTDAGIFGAGTTLTVLGQSSRSSSGGGSSGGGGSAVTLDESEGGLQTPGGALSLVCKASGFTFNNNGMAWVRQAPGKGLEFVAGISSGSYTYYGTAVKGRATISRDNGQSTVRLQLNNLRAEDTATYFCAKDGSDYNWNSGADSIDAWGHGTEVIVSS (서열번호 119)

[0682] 실시예 4-2. 마우스 CD4 T세포 결합능 확인 (in vitro)

[0683] An experiment was conducted to evaluate the T cell binding ability of the mouse anti-CD40L / anti-CD28 bispecific antibody (PV1x2-12-C) manufactured in Example 4-1. CD4 T cells were isolated from the spleen and lymph nodes of the mouse using the MACS method (mouse CD4 microbead, 130-117-043 Miltenyi Biotech), and then stimulated in vitro with plate-bound aCD3 (clone 145-2C11, BE0001-1, Bio X Cell, 10ug / ml) and aCD28 (clone 37.51, 553294 BD bioscience, 2ug / ml) for 48 hours to induce CD40L expression on CD4 T cells.

[0684]

[0685] After binding the PV1x2-12-C antibody to activated CD4 T cells, the binding of the antibody was measured by flow cytometry using a fluorescent anti-Ck antibody, and it was confirmed that the PV1x2-12-C antibody bound to activated mouse CD4 T cells (Fig. 69).

[0686]

[0687] Example 4-3. Confirmation of T cell suppression ability (in vitro)

[0688] We evaluated whether the above-mentioned anti-CD40L / anti-CD28 bispecific antibody for mice (PV1x2-12-C) could simultaneously bind to CD40L and CD28 of CD4 T cells, block CD40L-CD40 and CD28-B7 binding, and consequently inhibit CD4 T cell activation.

[0689] Mouse bone marrow cells were isolated and differentiated into dendritic cells by culturing with GMCSF (20 ng / ml, JW Creagene, rmGM-CSF) and IL-4 (20 ng / ml, JW Creagene, rmIL-4) for 5 days. CD4 T cells were isolated from the spleen and lymph nodes of the mouse using the MACS method, and then mouse CD4 T cells and dendritic cells were co-cultured, followed by the addition of anti-mouse CD3 antibody (1 ug / ml) for TCR stimulation. The T cell suppressive efficacy of the bispecific antibody was evaluated by adding the mouse anti-CD40L / anti-CD28 bispecific antibody (PV1x2-12-C) to the co-culture conditions.

[0690]

[0691] After 48 hours, the supernatant was separated and the T cell activating cytokines IFNr (IFN-r ELISA set, BDB555138, BD bioscience) and IL2 (IL-2 ELISA set, BDB555148, BD bioscience) were measured using the ELISA method. As a result, it was confirmed that the secretion of IFNr and IL2 in the group treated with PV1x2-12-C was significantly reduced compared to the negative control group.

[0692] This suggests that the mouse anti-CD40L / anti-CD28 bispecific antibody suppressed T cell activity by blocking the CD40L, CD28 signals of CD4 T cells, similar to the experimental results of the anti-CD40L / anti-CD28 bispecific antibody that underwent the humanization process in Example 3 (Figure 70).

[0693]

[0694] Example 4-4. Evaluation of the ability to suppress autoimmune diseases

[0695] In Example 4-3, it was confirmed that the anti-CD40L / anti-CD28 bispecific antibody for mice (PV1x2-12-C) suppressed T cells similarly to the anti-CD40L / anti-CD28 bispecific antibody that underwent the humanization process. Therefore, an experiment was conducted to confirm whether the anti-CD40L / anti-CD28 bispecific antibody for mice could suppress autoimmune T cells in vivo and thereby suppress autoimmune diseases.

[0696] We established an experimental autoimmune encephalomyelitis (EAE) mouse model, an animal model of multiple sclerosis, an autoimmune disease of the central nervous system, and verified the efficacy of anti-CD40LxCD28 antibodies. An experiment was conducted to induce autoimmune demyelinating disease in WT C57BL / 6 mice (C57BL / 6, Orient Bio) by subcutaneously injecting a neuromyelin autoantigen peptide (MOG peptide, Peptron, 200ug / mouse) together with a large amount of Complete Freuds Adjuvant (Incomplete Freuds Adjuvant (IFA) + Killed mycobacterium tuberculosis, 1000ug / mouse), (IFA, F5506, Sigma-Aldrich) (Killed mycobacterium tuberculosis, 231141, BD Biosciences) and pertussis toxin (P7208, Sigma-Aldrich). An anti-CD40L / anti-CD28 bispecific antibody for mice (PV1x2-12-C) was injected intraperitoneally to confirm that the progression of the disease could be inhibited. As single antibody controls, a bispecific antibody was used that linked each single antibody (PV1 and 2-12-C clones, scFv) and the scFv of an anti-cotinine antibody (Korean Patent Publication No. KR 10-2019-0023084 A) (Cotx2-12-C; PV1xCot, see Example 1-1).

[0697] The results of intraperitoneal injection of 200 ug of antibody per mouse at two-day intervals for a total of six times and monitoring the progression of the disease over time are shown in Figure 71.

[0698]

[0699] As shown in Figure 71, in the control group that was not treated with antibodies, the mean clinical score increased over time, confirming the progression of the disease. In the case of treatment with the single antibody control group (Cotx2-12-C; PV1xCot), the progression of the disease was partially suppressed compared to the group that was not treated with antibodies, confirming the partial efficacy of the single antibody. In the group treated with dual antibodies (PV1x2-12-C), the clinical severity of the disease was confirmed to be significantly lower, confirming that the dual specific antibody effectively suppresses autoimmune demyelinating disease.

[0700] These experimental results should be interpreted as supporting the excellent effect of the anti-CD40L / anti-CD28 bispecific antibody, which is a newly proposed antibody in this application, which is linked to an antigen-binding fragment of an anti-CD40L antibody that does not include an Fc region and an antigen-binding fragment of an anti-CD28 antibody in a monovalent antibody form, by simultaneously inhibiting two co-stimulatory molecules without causing side effects such as thrombosis, and can effectively suppress autoimmune diseases.

[0701]

[0702] From the above description, those skilled in the art will understand that the present invention can be implemented in other specific forms without altering its technical spirit or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as encompassing all changes or modifications derived from the meaning and scope of the following claims and their equivalent concepts, rather than the detailed description above.

Claims

1. Anti-CD40L / anti-CD28 bispecific antibodies containing: (1) an antigen-binding fragment of an anti-CD40L antibody that does not contain an Fc region; and (2) Antigen-binding fragment of anti-CD28 antibody in monovalent antibody form.

2. In paragraph 1, (1) The antigen-binding fragment of the above anti-CD40L antibody is in the form of an anti-CD40L scFv, Fv, (scFv)2, Fab, Fab', F(ab')2 or single domain antibody without an Fc region, (2) The antigen-binding fragment of the above anti-CD28 antibody is in the form of a single domain antibody in the form of anti-CD28 scFv, Fv, Fab, Fab' or monovalent antibody. Anti-CD40L / anti-CD28 bispecific antibody.

3. In paragraph 1, (1) The antigen-binding fragment of the above anti-CD40L antibody is anti-CD40L scFv, (2) The antigen-binding fragment of the above anti-CD28 antibody is anti-CD28 scFv. Anti-CD40L / anti-CD28 bispecific antibody.

4. In the first paragraph, the anti-CD40L / anti-CD28 bispecific antibody is an anti-CD40L / anti-CD28 bispecific antibody in which the anti-CD40L scFv and the anti-CD28 scFv are linked by the constant region (C kappa) of the light chain of an IgG antibody.

5. In paragraph 1, 1) The antigen-binding fragment of the above anti-CD40L antibody is, L-CDR1 comprising the amino acid sequence of SEQ ID NO: 1 or 2; L-CDR2 comprising the amino acid sequence of SEQ ID NO: 4 or 5; L-CDR3 comprising the amino acid sequence of SEQ ID NO: 7 or 8; H-CDR1 comprising the amino acid sequence of SEQ ID NO: 10 or 11; H-CDR2 comprising the amino acid sequence of SEQ ID NO: 13 or 14; and Comprising an H-CDR3 comprising the amino acid sequence of SEQ ID NO: 16 or 17; 2) The antigen-binding fragment of the above anti-CD28 antibody is, L-CDR1 comprising the amino acid sequence of SEQ ID NO: 65; L-CDR2 comprising the amino acid sequence of SEQ ID NO: 66; L-CDR3 comprising the amino acid sequence of SEQ ID NO: 67; H-CDR1 comprising the amino acid sequence of SEQ ID NO: 68 or 69; H-CDR2 comprising the amino acid sequence of SEQ ID NO: 70; and Comprising an H-CDR3 comprising the amino acid sequence of sequence number 71, Anti-CD40L / anti-CD28 bispecific antibody.

6. In paragraph 5, 1) The antigen-binding fragment of the above anti-CD40L antibody is, (1) L-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, L-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, L-CDR3 comprising the amino acid sequence of SEQ ID NO: 7, H-CDR1 comprising the amino acid sequence of SEQ ID NO: 10, H-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and H-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; or (2) L-CDR1 comprising an amino acid sequence of SEQ ID NO: 2, L-CDR2 comprising an amino acid sequence of SEQ ID NO: 5, L-CDR3 comprising an amino acid sequence of SEQ ID NO: 8, H-CDR1 comprising an amino acid sequence of SEQ ID NO: 11, H-CDR2 comprising an amino acid sequence of SEQ ID NO: 14, and H-CDR3 comprising an amino acid sequence of SEQ ID NO: 17; 2) The antigen-binding fragment of the above anti-CD28 antibody is, An L-CDR1 comprising an amino acid sequence of SEQ ID NO: 65; an L-CDR2 comprising an amino acid sequence of SEQ ID NO: 66; an L-CDR3 comprising an amino acid sequence of SEQ ID NO: 67; an H-CDR1 comprising an amino acid sequence of SEQ ID NO: 68 or 69; an H-CDR2 comprising an amino acid sequence of SEQ ID NO: 70; and an H-CDR3 comprising an amino acid sequence of SEQ ID NO:

71. Anti-CD40L / anti-CD28 bispecific antibody.

7. In paragraph 5, 1) The antigen-binding fragment of the above anti-CD40L antibody is, (1) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 47, 48, 49 or 128; and (2) comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 51, 52, 53, 54, 55, or 56; 2) The antigen-binding fragment of the above anti-CD28 antibody is, (1) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 87, 88, 98 or 100; and (2) comprising a heavy chain variable region comprising the amino acid sequence of sequence number 89, 90, 99 or 101; Anti-CD40L / anti-CD28 bispecific antibody.

8. In paragraph 5, 1) The antigen-binding fragment of the above anti-CD40L antibody is, (1) a light chain variable region comprising an amino acid sequence of SEQ ID NO: 47; and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 51; (2) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 48 or 128; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 52, 53, 54, or 55; or (3) a light chain variable region comprising an amino acid sequence of SEQ ID NO: 49; and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 56; 2) The antigen-binding fragment of the above anti-CD28 antibody is, (1) a light chain variable region comprising an amino acid sequence of SEQ ID NO: 87; and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 89; (2) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 88; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 90; (3) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 98; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 99; (4) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 99; or (5) a light chain variable region comprising an amino acid sequence of SEQ ID NO: 98; and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:

101. Anti-CD40L / anti-CD28 bispecific antibody.

9. In paragraph 5, the anti-CD40L / anti-CD28 bispecific antibody is an anti-CD40L / anti-CD28 bispecific antibody in which the anti-CD40L scFv and the anti-CD28 scFv are linked by the constant region (C kappa) of the light chain of an IgG antibody.

10. An anti-CD40L / anti-CD28 bispecific antibody according to claim 9, wherein the constant region of the light chain of the IgG antibody comprises the amino acid sequence of SEQ ID NO:

95.

11. A pharmaceutical composition for the prevention or treatment of at least one autoimmune disease and graft-versus-host disease, comprising an anti-CD40L / anti-CD28 bispecific antibody according to any one of claims 1 to 10.

12. A pharmaceutical composition according to claim 11, wherein the autoimmune disease is caused by T cell overexpression.

13. In claim 11, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes, Crohn's disease, scleroderma, Sjogren's syndrome, psoriasis, inflammatory bowel disease, ulcerative colitis, ankylosing spondylitis, interstitial lung disease, uveitis, optic neuritis, peripheral neuropathies, sarcoidosis, antiphospholipid syndrome, inflammatory myopathies, Behcet's disease A pharmaceutical composition comprising at least one selected from the group consisting of Behcet's disease, alopecia areata / universalis, pemphigus vulgaris, myasthenia gravis, Graves' disease, Hashimoto's thyroiditis, Guillain-Barre syndrome, celiac disease, and pernicious anemia.

14. A pharmaceutical composition according to claim 11, wherein the graft-versus-host disease is at least one selected from the group consisting of acute graft-versus-host disease and chronic graft-versus-host disease.

15. Anti-CD40L antibodies or antigen-binding fragments thereof comprising: L-CDR1 comprising the amino acid sequence of SEQ ID NO: 1 or 2; L-CDR2 comprising the amino acid sequence of SEQ ID NO: 4 or 5; L-CDR3 comprising the amino acid sequence of SEQ ID NO: 7 or 8; H-CDR1 comprising the amino acid sequence of SEQ ID NO: 10 or 11; H-CDR2 comprising the amino acid sequence of SEQ ID NO: 13 or 14; and H-CDR3 comprising the amino acid sequence of SEQ ID NO: 16 or 17.

16. In paragraph 15, (1) L-CDR1 comprising the amino acid sequence of SEQ ID NO: 1, L-CDR2 comprising the amino acid sequence of SEQ ID NO: 4, L-CDR3 comprising the amino acid sequence of SEQ ID NO: 7, H-CDR1 comprising the amino acid sequence of SEQ ID NO: 10, H-CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and H-CDR3 comprising the amino acid sequence of SEQ ID NO: 16; or (2) An anti-CD40L antibody or antigen-binding fragment thereof, comprising an L-CDR1 comprising an amino acid sequence of SEQ ID NO: 2, an L-CDR2 comprising an amino acid sequence of SEQ ID NO: 5, an L-CDR3 comprising an amino acid sequence of SEQ ID NO: 8, an H-CDR1 comprising an amino acid sequence of SEQ ID NO: 11, an H-CDR2 comprising an amino acid sequence of SEQ ID NO: 14, and an H-CDR3 comprising an amino acid sequence of SEQ ID NO:

17.

17. In paragraph 15, A light chain variable region comprising the amino acid sequence of SEQ ID NO: 47, 48, 49, or 128; and An anti-CD40L antibody or antigen-binding fragment thereof, comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 51, 52, 53, 54, 55, or 56.

18. In paragraph 15, (1) a light chain variable region comprising an amino acid sequence of SEQ ID NO: 47; and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 51; (2) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 48 or 128; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 52, 53, 54, or 55; or (3) An anti-CD40L antibody or antigen-binding fragment thereof, comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 49; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:

56.

19. An anti-CD40L antibody or antigen-binding fragment thereof, characterized in that the anti-CD40L antibody or antigen-binding fragment thereof in claim 15 does not contain an Fc region.

20. In claim 15, the anti-CD40L antibody or antigen-binding fragment thereof is in the form of an anti-CD40L scFv, Fv, (scFv)2, Fab, Fab', F(ab')2 or single domain antibody without an Fc region.

21. In claim 15, the anti-CD40L antibody or antigen-binding fragment thereof is an anti-CD40L scFv.

22. A pharmaceutical composition for the prevention or treatment of at least one autoimmune disease and graft-versus-host disease, comprising an anti-CD40L antibody or an antigen-binding fragment thereof according to any one of claims 15 to 21.

23. A pharmaceutical composition according to claim 22, wherein the autoimmune disease is caused by T cell overactivation. 24.An anti-CD28 antibody or antigen-binding fragment thereof comprising: L-CDR1 comprising the amino acid sequence of SEQ ID NO: 65; L-CDR2 comprising the amino acid sequence of SEQ ID NO: 66; L-CDR3 comprising the amino acid sequence of SEQ ID NO: 67; H-CDR1 comprising the amino acid sequence of SEQ ID NO: 68 or 69; H-CDR2 comprising the amino acid sequence of SEQ ID NO: 70; and H-CDR3 comprising the amino acid sequence of SEQ ID NO:

71.

25. In paragraph 24, (1) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 87, 88, 98 or 100; and (2) An anti-CD28 antibody or antigen-binding fragment thereof comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 89, 90, 99 or 101.

26. In paragraph 24, (1) a light chain variable region comprising an amino acid sequence of SEQ ID NO: 87; and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO: 89; (2) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 88; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 90; (3) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 98; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 99; (4) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 100; and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 99; or (5) a light chain variable region comprising an amino acid sequence of SEQ ID NO: 98; and a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:

101. Anti-CD28 antibody or antigen-binding fragment thereof.

27. In claim 24, the antigen-binding fragment of the anti-CD28 antibody is in the form of a monovalent antibody, or an antigen-binding fragment thereof.

28. In claim 24, the antigen-binding fragment of the anti-CD28 antibody is in the form of a single domain antibody in the form of an anti-CD28 scFv, Fv, Fab, Fab' or monovalent antibody, or an antigen-binding fragment thereof.

29. In claim 24, the anti-CD28 antibody or antigen-binding fragment thereof is an anti-CD28 scFv.

30. A pharmaceutical composition for the prevention or treatment of at least one autoimmune disease and graft-versus-host disease, comprising an anti-CD40L antibody or an antigen-binding fragment thereof according to any one of claims 24 to 29.

31. A pharmaceutical composition according to claim 30, wherein the autoimmune disease is caused by T cell overactivation.

Citation Information

Patent Citations

  • New derivative of piperazine.

    FR104M

  • Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies

    US5885573A

  • System and Method for Determining Whether an Object Detection Sensor in a Smart Farm is Faulty

    KR1020230058887A

  • Electronic device for providing alaram for crying of child, and operation method of the same

    KR1020240066868A

  • Antibody complexes

    WO2006138670A2